```
  result in loss of user privileges and other penalties.

* * * * * * * * * * * * * * * * STN  Columbus  * * * * * * * * * * * * * * * *

FILE 'HOME' ENTERED AT 10:25:20 ON 23 JAN 2007

=> file .meeting
'EVENTLINE' IS NOT A VALID FILE NAME
Enter "HELP FILE NAMES" at an arrow prompt (=>) for a list of files
that are available.  If you have requested multiple files, you can
specify a corrected file name or you can enter "IGNORE" to continue
accessing the remaining file names entered.
ENTER A FILE NAME OR (IGNORE):ignore
'MEDICONF' IS NOT A VALID FILE NAME
Enter "HELP FILE NAMES" at an arrow prompt (=>) for a list of files
that are available.  If you have requested multiple files, you can
specify a corrected file name or you can enter "IGNORE" to continue
accessing the remaining file names entered.
ENTER A FILE NAME OR (IGNORE):ignore
COST IN U.S. DOLLARS                                SINCE FILE      TOTAL
                                                       ENTRY    SESSION
FULL ESTIMATED COST                                     0.21       0.21

FILE 'AGRICOLA' ENTERED AT 10:25:39 ON 23 JAN 2007

FILE 'BIOTECHNO' ENTERED AT 10:25:39 ON 23 JAN 2007
COPYRIGHT (C) 2007 Elsevier Science B.V., Amsterdam. All rights reserved.

FILE 'CONFSCI' ENTERED AT 10:25:39 ON 23 JAN 2007
COPYRIGHT (C) 2007 Cambridge Scientific Abstracts (CSA)

FILE 'HEALSAFE' ENTERED AT 10:25:39 ON 23 JAN 2007
COPYRIGHT (C) 2007 Cambridge Scientific Abstracts (CSA)


FILE 'IMSDRUGCONF' ENTERED AT 10:25:39 ON 23 JAN 2007
COPYRIGHT (C) 2007 IMSWORLD Publications Ltd.

FILE 'LIFESCI' ENTERED AT 10:25:39 ON 23 JAN 2007
COPYRIGHT (C) 2007 Cambridge Scientific Abstracts (CSA)


FILE 'PASCAL' ENTERED AT 10:25:39 ON 23 JAN 2007
Any reproduction or dissemination in part or in full,
by means of any process and on any support whatsoever
is prohibited without the prior written agreement of INIST-CNRS.
COPYRIGHT (C) 2007 INIST-CNRS. All rights reserved.

=> DKFZp434P1818.1
L1             0 FILE AGRICOLA
L2             0 FILE BIOTECHNO
L3             0 FILE CONFSCI
L4             0 FILE HEALSAFE
L5             0 FILE IMSDRUGCONF
L6             0 FILE LIFESCI
L7             0 FILE PASCAL

TOTAL FOR ALL FILES
L8             0 DKFZP434P1818.1

=> file .jacob
COST IN U.S. DOLLARS                                SINCE FILE      TOTAL
                                                       ENTRY    SESSION
FULL ESTIMATED COST                                     7.00       7.21
```

```
FILE 'CAPLUS' ENTERED AT 10:26:12 ON 23 JAN 2007
USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT.
PLEASE SEE "HELP USAGETERMS" FOR DETAILS.
COPYRIGHT (C) 2007 AMERICAN CHEMICAL SOCIETY (ACS)

FILE 'BIOSIS' ENTERED AT 10:26:12 ON 23 JAN 2007
Copyright (c) 2007 The Thomson Corporation

FILE 'MEDLINE' ENTERED AT 10:26:12 ON 23 JAN 2007

FILE 'EMBASE' ENTERED AT 10:26:12 ON 23 JAN 2007
Copyright (c) 2007 Elsevier B.V. All rights reserved.

FILE 'USPATFULL' ENTERED AT 10:26:12 ON 23 JAN 2007
CA INDEXING COPYRIGHT (C) 2007 AMERICAN CHEMICAL SOCIETY (ACS)

=> DKFZp434P1818.1
L9            1 FILE CAPLUS
L10           0 FILE BIOSIS
L11           0 FILE MEDLINE
L12           0 FILE EMBASE
L13           1 FILE USPATFULL

TOTAL FOR ALL FILES
L14           2 DKFZP434P1818.1

=> dup rem
ENTER L# LIST OR (END):l14
PROCESSING COMPLETED FOR L14
L15            2 DUP REM L14 (0 DUPLICATES REMOVED)

=> d l15 ibib abs total

L15  ANSWER 1 OF 2  USPATFULL on STN
ACCESSION NUMBER:        2005:56659  USPATFULL
TITLE:                   Biomarkers for diagnosing rheumatoid arthritis
INVENTOR(S):             Kantor, Aaron B., San Carlos, CA, UNITED STATES
                         Becker, Christopher, Palo Alto, CA, UNITED STATES
                         Schulman, Howard, Palo Alto, CA, UNITED STATES

                              NUMBER        KIND    DATE
                         ---------------- ------ --------
PATENT INFORMATION:      US 2005048574      A1   20050303
APPLICATION INFO.:       US 2004-801990     A1   20040315  (10)

                               NUMBER         DATE
                         ------------------ --------
PRIORITY INFORMATION:    US 2003-455037P    20030314 (60)
DOCUMENT TYPE:           Utility
FILE SEGMENT:            APPLICATION
LEGAL REPRESENTATIVE:    SWANSON & BRATSCHUN L.L.C., 1745 SHEA CENTER DRIVE,
                         SUITE 330, HIGHLANDS RANCH, CO, 80129
NUMBER OF CLAIMS:        52
EXEMPLARY CLAIM:         1
LINE COUNT:              6315
CAS INDEXING IS AVAILABLE FOR THIS PATENT.
AB     Biological markers for rheumatoid arthritis (RA) are disclosed. Also
       disclosed are the uses of such markers to diagnose and treat RA, monitor
       progression of the disease, evaluate therapeutic interventions, and
       screen candidate drugs in a clinical or preclinical trial.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.
```

L15 ANSWER 2 OF 2 CAPLUS COPYRIGHT 2007 ACS on STN
ACCESSION NUMBER: 2004:799449 CAPLUS
DOCUMENT NUMBER: 141:294121
TITLE: Protein markers in body fluids for diagnosing rheumatoid arthritis
INVENTOR(S): Kantor, Aaron B.; Becker, Christopher H.; Schulman, Howard
PATENT ASSIGNEE(S): Surromed Inc., USA; Ppd Biomarker Discovery Sciences, LLC
SOURCE: PCT Int. Appl., 184 pp.
CODEN: PIXXD2
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2004082617	A2	20040930	WO 2004-US7880	20040315
WO 2004082617	A3	20051208		
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW				
RW: BW, GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG				
AU 2004222345	A1	20040930	AU 2004-222345	20040315
CA 2527916	A1	20040930	CA 2004-2527916	20040315
US 2005048574	A1	20050303	US 2004-801990	20040315
EP 1627076	A2	20060222	EP 2004-720815	20040315
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR, BG, CZ, EE, HU, PL, SK				

PRIORITY APPLN. INFO.: US 2003-455037P P 20030314
WO 2004-US7880 W 20040315

AB Biol. markers for rheumatoid arthritis (RA) are disclosed. A high-mol.-weight fraction separated from serum samples from patients with RA or from non-RA subjects was subjected to tryptic digestion, and the peptides profiles by liquid chromatog.-electrospray ionization-mass spectrometry (LC-ESI-MS) on a high-resolution time-of-flight (TOF) instrument. Peptide markers whose expression is elevated in RA or decreased in RA are identified. Such markers may be used to diagnose and treat RA, monitor progression of the disease, evaluate therapeutic interventions, and screen candidate drugs in a clin. or preclin. trial.

=> file .chemistry

COST IN U.S. DOLLARS	SINCE FILE ENTRY	TOTAL SESSION
FULL ESTIMATED COST	13.58	20.79

DISCOUNT AMOUNTS (FOR QUALIFYING ACCOUNTS)	SINCE FILE ENTRY	TOTAL SESSION
CA SUBSCRIBER PRICE	-0.78	-0.78

FILE 'CAPLUS' ENTERED AT 10:26:50 ON 23 JAN 2007

```
FILE 'BIOTECHNO' ENTERED AT 10:26:50 ON 23 JAN 2007
COPYRIGHT (C) 2007 Elsevier Science B.V., Amsterdam. All rights reserved.

FILE 'COMPENDEX' ENTERED AT 10:26:50 ON 23 JAN 2007
Compendex Compilation and Indexing (C) 2007
Elsevier Engineering Information Inc (EEI). All rights reserved.
Compendex (R) is a registered Trademark of Elsevier Engineering Information Inc.

FILE 'ANABSTR' ENTERED AT 10:26:50 ON 23 JAN 2007
COPYRIGHT (c) 2007 THE ROYAL SOCIETY OF CHEMISTRY (RSC)

FILE 'CERAB' ENTERED AT 10:26:50 ON 23 JAN 2007
COPYRIGHT (C) 2007 Cambridge Scientific Abstracts (CSA)

FILE 'METADEX' ENTERED AT 10:26:50 ON 23 JAN 2007
COPYRIGHT (c) 2007 Cambridge Scientific Abstracts (CSA)

FILE 'USPATFULL' ENTERED AT 10:26:50 ON 23 JAN 2007
CA INDEXING COPYRIGHT (C) 2007 AMERICAN CHEMICAL SOCIETY (ACS)

=> DKFZp434P1818.1
L16             1 FILE CAPLUS
L17             0 FILE BIOTECHNO
L18             0 FILE COMPENDEX
L19             0 FILE ANABSTR
L20             0 FILE CERAB
L21             0 FILE METADEX
L22             1 FILE USPATFULL

TOTAL FOR ALL FILES
L23             2 DKFZP434P1818.1

=> DKFZp434
L24             1 FILE CAPLUS
L25             0 FILE BIOTECHNO
L26             0 FILE COMPENDEX
L27             0 FILE ANABSTR
L28             0 FILE CERAB
L29             0 FILE METADEX
L30             8 FILE USPATFULL

TOTAL FOR ALL FILES
L31             9 DKFZP434

=> KIAA1902
L32             6 FILE CAPLUS
L33             0 FILE BIOTECHNO
L34             0 FILE COMPENDEX
L35             0 FILE ANABSTR
L36             0 FILE CERAB
L37             0 FILE METADEX
L38             6 FILE USPATFULL

TOTAL FOR ALL FILES
L39            12 KIAA1902

=> dup rem
ENTER L# LIST OR (END):l39
PROCESSING COMPLETED FOR L39
L40            11 DUP REM L39 (1 DUPLICATE REMOVED)

=> d l40 ibib abs total

L40  ANSWER 1 OF 11  USPATFULL on STN
```

ACCESSION NUMBER: 2006:92771 USPATFULL
TITLE: Molecular toxicology modeling
INVENTOR(S): Mendrick, Donna, Gaithersburg, MD, UNITED STATES
Porter, Mark, Gaithersburg, MD, UNITED STATES
Johnson, Kory, Gaithersburg, MD, UNITED STATES
Higgs, Brandon, Gaithersburg, MD, UNITED STATES
Castle, Arthur, Gaithersburg, MD, UNITED STATES
Elashoff, Michael, Gaithersburg, MD, UNITED STATES
PATENT ASSIGNEE(S): GENE LOGIC, INC. (U.S. corporation)

	NUMBER	KIND	DATE
PATENT INFORMATION:	US 2006078900	A1	20060413
APPLICATION INFO.:	US 2005-36196	A1	20050118 (11)

RELATED APPLN. INFO.: Division of Ser. No. US 2002-152319, filed on 22 May 2002, PENDING

	NUMBER	DATE
PRIORITY INFORMATION:	US 2001-292335P	20010522 (60)
	US 2001-297523P	20010613 (60)
	US 2001-298925P	20010619 (60)
	US 2001-303810P	20010710 (60)
	US 2001-303807P	20010710 (60)
	US 2001-303808P	20010710 (60)
	US 2001-315047P	20010828 (60)
	US 2001-324928P	20010927 (60)
	US 2001-330867P	20011101 (60)
	US 2001-330462P	20011022 (60)
	US 2001-331805P	20011121 (60)
	US 2001-336144P	20011206 (60)
	US 2001-340873P	20011219 (60)
	US 2002-357843P	20020221 (60)
	US 2002-357842P	20020221 (60)
	US 2002-357844P	20020221 (60)
	US 2002-364134P	20020315 (60)
	US 2002-370206P	20020408 (60)
	US 2002-370247P	20020408 (60)
	US 2002-370144P	20020408 (60)
	US 2002-371679P	20020412 (60)
	US 2002-372794P	20020417 (60)

DOCUMENT TYPE: Utility
FILE SEGMENT: APPLICATION
LEGAL REPRESENTATIVE: MORGAN LEWIS & BOCKIUS LLP, 1111 PENNSYLVANIA AVENUE NW, WASHINGTON, DC, 20004, US
NUMBER OF CLAIMS: 2
EXEMPLARY CLAIM: 1
LINE COUNT: 28570
CAS INDEXING IS AVAILABLE FOR THIS PATENT.
AB The present invention is based on the elucidation of the global changes in gene expression and the identification of toxicity markers in tissues or cells exposed to a known renal toxin. The genes may be used as toxicity markers in drug screening and toxicity assays. The invention includes a database of genes characterized by toxin-induced differential expression that is designed for use with microarrays and other solid-phase probes.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L40 ANSWER 2 OF 11 USPATFULL on STN
ACCESSION NUMBER: 2006:27403 USPATFULL
TITLE: Tissue-specific imaging and therapeutic agents targeting proteins expressed on lung endothelial cell surface

INVENTOR(S): Schnitzer, Jan E., Encinitas, CA, UNITED STATES
Oh, Philip, San Diego, CA, UNITED STATES
PATENT ASSIGNEE(S): Sidney Kimmel Cancer Center, San Diego, CA, UNITED STATES (U.S. corporation)

	NUMBER	KIND	DATE
PATENT INFORMATION:	US 2006024231	A1	20060202
APPLICATION INFO.:	US 2005-143114	A1	20050602 (11)

	NUMBER	DATE
PRIORITY INFORMATION:	US 2004-576114P	20040602 (60)

DOCUMENT TYPE: Utility
FILE SEGMENT: APPLICATION
LEGAL REPRESENTATIVE: HAMILTON, BROOK, SMITH & REYNOLDS, P.C., 530 VIRGINIA ROAD, P.O. BOX 9133, CONCORD, MA, 01742-9133, US
NUMBER OF CLAIMS: 40
EXEMPLARY CLAIM: 1
LINE COUNT: 3710
CAS INDEXING IS AVAILABLE FOR THIS PATENT.
AB Methods of delivering an agent in a tissue-specific manner, particularly lung tissue, by targeting a protein expressed on the endothelial cell surface, are described. The methods can be used for detecting, imaging and/or treating pathologies, as well as for diagnostics.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L40 ANSWER 3 OF 11 CAPLUS COPYRIGHT 2007 ACS on STN DUPLICATE 1
ACCESSION NUMBER: 2005:394682 CAPLUS
DOCUMENT NUMBER: 142:445550
TITLE: Gene expression profiles for the diagnosis and prognosis of breast cancer
INVENTOR(S): Erlander, Mark; Ma, Xiao-Jun; Wang, Wei; Wittliff, James L.
PATENT ASSIGNEE(S): Arcturus Bioscience, Inc. University of Louisville, USA
SOURCE: U.S. Pat. Appl. Publ., 40 pp.
CODEN: USXXCO
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
US 2005095607	A1	20050505	US 2004-795092	20040305
WO 2005098037	A1	20051020	WO 2004-US6760	20040305
WO 2005098037	A8	20060209		
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW				
RW: BW, GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG				
EP 1651772	A1	20060503	EP 2004-718019	20040305
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR, BG, CZ, EE, HU, PL, SK				

PRIORITY APPLN. INFO.: US 2003-453006P P 20030307

WO 2004-US6760 W 20040305

AB The invention relates to the identification and use of gene expression profiles, or patterns, suitable for identification of breast cancer patient populations with different survival outcomes. The gene expression profiles may be embodied in nucleic acid expression, protein expression, or other expression formats, and may be used in the study and/or determination of the prognosis of a patient, including breast cancer survival.

L40 ANSWER 4 OF 11 CAPLUS COPYRIGHT 2007 ACS on STN
ACCESSION NUMBER: 2005:1311323 CAPLUS
DOCUMENT NUMBER: 144:47000
TITLE: Lung endothelial cell associated marker proteins as targets for tissue-specific imaging and therapeutical agents in diagnosis and therapy
INVENTOR(S): Schnitzer, Jan E.; Oh, Phillip
PATENT ASSIGNEE(S): Sidney Kimmel Cancer Center, USA
SOURCE: PCT Int. Appl., 84 pp.
CODEN: PIXXD2
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2005117977	A2	20051215	WO 2005-US19398	20050602
WO 2005117977	A3	20060202		
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KM, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NG, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SM, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW				
RW: BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IS, IT, LT, LU, MC, NL, PL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG				
US 2006024231	A1	20060202	US 2005-143114	20050602

PRIORITY APPLN. INFO.: US 2004-576114P P 20040602

AB Methods of delivering an agent in a tissue-specific manner, particularly lung tissue, by targeting a protein expressed on the endothelial cell surface, are described. The methods can be used for detecting, imaging and/or treating pathologies, as well as for diagnostics. Specifically claimed are a series of lung endothelial cell associated marker proteins for diagnostic and therapeutical uses, in particular TIE-2, APN, TEM4, TEM6, ICAM-1, nucleolin, P2Z receptor, Trk-A, FLJ10849, HSPA12B, APP, and OX-45.

L40 ANSWER 5 OF 11 USPATFULL on STN
ACCESSION NUMBER: 2005:75183 USPATFULL
TITLE: Association of FHOD2 with common type 2 diabetes mellitus
INVENTOR(S): Dong, Shoulian, San Jose, CA, UNITED STATES
PATENT ASSIGNEE(S): Affymetrix, INC., Santa Clara, CA (U.S. corporation)

	NUMBER	KIND	DATE	
PATENT INFORMATION:	US 2005064480	A1	20050324	
APPLICATION INFO.:	US 2004-917647	A1	20040813	(10)

	NUMBER	DATE

PRIORITY INFORMATION: US 2003-495624P 20030815 (60)
DOCUMENT TYPE: Utility
FILE SEGMENT: APPLICATION
LEGAL REPRESENTATIVE: AFFYMETRIX, INC, ATTN: CHIEF IP COUNSEL, LEGAL DEPT., 3380 CENTRAL EXPRESSWAY, SANTA CLARA, CA, 95051
NUMBER OF CLAIMS: 20
EXEMPLARY CLAIM: 1
NUMBER OF DRAWINGS: 1 Drawing Page(s)
LINE COUNT: 1209
CAS INDEXING IS AVAILABLE FOR THIS PATENT.
AB FHOD2 has been identified as a type 2 diabetes susceptibility gene. Methods for diagnosing and treating type 2 diabetes and methods for identifying compounds for use in the diagnosis and treatment of diabetes are disclosed. Improved diagnostic methods for early detection of a risk for developing type 2 diabetes mellitus in humans, and screening assays for therapeutic agents useful in the treatment of type 2 diabetes mellitus, by analyzing the FHOD2 gene or gene products from FHOD2, including variants forms of FHOD2, are disclosed. Indicators of diabetes include variant forms of the FHOD2 protein, variant forms of FHOD2 pre-mRNA or mRNA or variant forms of the genomic DNA of the FHOD2 gene or DNA surrounding FHOD2.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L40 ANSWER 6 OF 11 USPATFULL on STN
ACCESSION NUMBER: 2005:56659 USPATFULL
TITLE: Biomarkers for diagnosing rheumatoid arthritis
INVENTOR(S): Kantor, Aaron B., San Carlos, CA, UNITED STATES
Becker, Christopher, Palo Alto, CA, UNITED STATES
Schulman, Howard, Palo Alto, CA, UNITED STATES

	NUMBER	KIND	DATE
PATENT INFORMATION:	US 2005048574	A1	20050303
APPLICATION INFO.:	US 2004-801990	A1	20040315 (10)

	NUMBER	DATE
PRIORITY INFORMATION:	US 2003-455037P	20030314 (60)

DOCUMENT TYPE: Utility
FILE SEGMENT: APPLICATION
LEGAL REPRESENTATIVE: SWANSON & BRATSCHUN L.L.C., 1745 SHEA CENTER DRIVE, SUITE 330, HIGHLANDS RANCH, CO, 80129
NUMBER OF CLAIMS: 52
EXEMPLARY CLAIM: 1
LINE COUNT: 6315
CAS INDEXING IS AVAILABLE FOR THIS PATENT.
AB Biological markers for rheumatoid arthritis (RA) are disclosed. Also disclosed are the uses of such markers to diagnose and treat RA, monitor progression of the disease, evaluate therapeutic interventions, and screen candidate drugs in a clinical or preclinical trial.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L40 ANSWER 7 OF 11 CAPLUS COPYRIGHT 2007 ACS on STN
ACCESSION NUMBER: 2004:799449 CAPLUS
DOCUMENT NUMBER: 141:294121
TITLE: Protein markers in body fluids for diagnosing rheumatoid arthritis
INVENTOR(S): Kantor, Aaron B.; Becker, Christopher H.; Schulman, Howard
PATENT ASSIGNEE(S): Surromed Inc., USA; Ppd Biomarker Discovery Sciences, LLC
SOURCE: PCT Int. Appl., 184 pp.

CODEN: PIXXD2
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2004082617	A2	20040930	WO 2004-US7880	20040315
WO 2004082617	A3	20051208		
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW				
RW: BW, GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG				
AU 2004222345	A1	20040930	AU 2004-222345	20040315
CA 2527916	A1	20040930	CA 2004-2527916	20040315
US 2005048574	A1	20050303	US 2004-801990	20040315
EP 1627076	A2	20060222	EP 2004-720815	20040315
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR, BG, CZ, EE, HU, PL, SK				

PRIORITY APPLN. INFO.: US 2003-455037P P 20030314
WO 2004-US7880 W 20040315

AB Biol. markers for rheumatoid arthritis (RA) are disclosed. A high-mol.-weight fraction separated from serum samples from patients with RA or from non-RA subjects was subjected to tryptic digestion, and the peptides profiles by liquid chromatog.-electrospray ionization-mass spectrometry (LC-ESI-MS) on a high-resolution time-of-flight (TOF) instrument. Peptide markers whose expression is elevated in RA or decreased in RA are identified. Such markers may be used to diagnose and treat RA, monitor progression of the disease, evaluate therapeutic interventions, and screen candidate drugs in a clin. or preclin. trial.

L40 ANSWER 8 OF 11 USPATFULL on STN
ACCESSION NUMBER: 2004:94708 USPATFULL
TITLE: Molecular toxicology modeling
INVENTOR(S): Mendrick, Donna, Gaithersburg, MD, UNITED STATES
Porter, Mark, Gaithersburg, MD, UNITED STATES
Johnson, Kory, Gaithersburg, MD, UNITED STATES
Higgs, Brandon, Gaithersburg, MD, UNITED STATES
Castle, Arthur, Gaithersburg, MD, UNITED STATES
Elashoff, Michael, Gaithersburg, MD, UNITED STATES

	NUMBER	KIND	DATE	
PATENT INFORMATION:	US 2004072160	A1	20040415	
APPLICATION INFO.:	US 2002-152319	A1	20020522	(10)

	NUMBER	DATE	
PRIORITY INFORMATION:	US 2001-292335P	20010522	(60)
	US 2001-297523P	20010613	(60)
	US 2001-298925P	20010619	(60)
	US 2001-303810P	20010710	(60)
	US 2001-303807P	20010710	(60)
	US 2001-303808P	20010710	(60)
	US 2001-315047P	20010828	(60)
	US 2001-324928P	20010927	(60)

	US 2001-330867P	20011101 (60)
	US 2001-330462P	20011022 (60)
	US 2001-331805P	20011121 (60)
	US 2001-336144P	20011206 (60)
	US 2001-340873P	20011219 (60)
	US 2002-357843P	20020221 (60)
	US 2002-357842P	20020221 (60)
	US 2002-357844P	20020221 (60)
	US 2002-364134P	20020315 (60)
	US 2002-370206P	20020408 (60)
	US 2002-370247P	20020408 (60)
	US 2002-370144P	20020408 (60)
	US 2002-371679P	20020412 (60)
	US 2002-372794P	20020417 (60)

DOCUMENT TYPE: Utility
FILE SEGMENT: APPLICATION
LEGAL REPRESENTATIVE: MORGAN LEWIS & BOCKIUS LLP, 1111 PENNSYLVANIA AVENUE NW, WASHINGTON, DC, 20004
NUMBER OF CLAIMS: 59
EXEMPLARY CLAIM: 1
LINE COUNT: 27909
CAS INDEXING IS AVAILABLE FOR THIS PATENT.

AB The present invention is based on the elucidation of the global changes in gene expression and the identification of toxicity markers in tissues or cells exposed to a known renal toxin. The genes may be used as toxicity markers in drug screening and toxicity assays. The invention includes a database of genes characterized by toxin-induced differential expression that is designed for use with microarrays and other solid-phase probes.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L40 ANSWER 9 OF 11 CAPLUS COPYRIGHT 2007 ACS on STN
ACCESSION NUMBER: 2003:347717 CAPLUS
DOCUMENT NUMBER: 139:47932
TITLE: Identification and characterization of human FMNL1, FMNL2 and FMNL3 genes in silico
AUTHOR(S): Katoh, Masuko; Katoh, Masaru
CORPORATE SOURCE: M&M Medical BioInformatics, Narashino, 275-0022, Japan
SOURCE: International Journal of Oncology (2003), 22(5), 1161-1168
CODEN: IJONES; ISSN: 1019-6439
PUBLISHER: International Journal of Oncology
DOCUMENT TYPE: Journal
LANGUAGE: English

AB FMNL (NM_005892.2) is a 5'-truncated partial cDNA encoding a Formin-homol. protein related to DAAM1, DAAM2, DIAPH1 and DIAPH2. Here, we identified three members of FMNL gene family in the human genome by using bioinformatics. FMNL1 gene, corresponding to 5'-truncated KW-13 and FMNL cDNAs, was located within reference genomic contig NT_010748.9 (nucleotide position 100576-125849, forward orientation). FMNL2 gene, corresponding to KIAA1902 and FHOD2 cDNAs, was located within NT_005151.10 (nucleotide position 122465-436828, forward orientation). FMNL3 gene, corresponding to 5'-truncated DKFZp762B245 and KIAA2014 cDNAs, was located within NT_026397.10 (nucleotide position 209769-279037, reverse orientation). FMNL1, FMNL2 and FMNL3 genes encode A and B isoforms with the C-terminal divergence due to alternative splicing (cassette splicing of exon 26). FMNL1A (1100 aa), FMNL1B (1114 aa), FMNL2A (1087 aa), FMNL2B (1093 aa), FMNL3A (1028 aa) and FMNL3B (1027 aa) consist of FDD, FH1 and FH2 domains. Total amino-acid identity were as follows: FMNL1A vs. FMNL2A, 59.3%; FMNL1A vs. FMNL3A, 56.1%; FMNL2A vs. FMNL3A, 68.6%. FMNL1 gene was mapped to human chromosome 17q21. FMNL2 gene was linked to FNBP3/HYPA gene on chromosome 2q23.3, while FMNL3 gene was linked to FNBP3L/HYPC gene on chromosome 12q13. FMNL1 mRNA was expressed in natural

killer cells, Burkitt lymphoma, pancreatic cancer, prostate cancer, and lung large cell carcinoma, FMNL2 mRNA in several normal tissues, diffuse-type gastric cancer, breast cancer, chondrosarcoma, melanoma, and glioblastoma, and FMNL3 mRNA in gastric cancer. FMNL1, FMNL2 and FMNL3 might be implicated in polarity control, invasion, migration, or metastasis through regulation of the Rho-related signaling pathway.

REFERENCE COUNT: 72 THERE ARE 72 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L40 ANSWER 10 OF 11 CAPLUS COPYRIGHT 2007 ACS on STN

ACCESSION NUMBER: 2003:992481 CAPLUS
DOCUMENT NUMBER: 140:194154
TITLE: Identification and characterization of human GRID2IP gene and rat Grid2ip gene in silico
AUTHOR(S): Katoh, Masuko; Katoh, Masaru
CORPORATE SOURCE: M and M Medical BioInformatics, Narashino, 275-0022, Japan
SOURCE: International Journal of Molecular Medicine (2003), 12(6), 1015-1019
CODEN: IJMMFG; ISSN: 1107-3756
PUBLISHER: International Journal of Molecular Medicine
DOCUMENT TYPE: Journal
LANGUAGE: English

AB Formin-homol. proteins are implicated in the cell polarity control through the assembly of specific actin structures. FMNL1/KW - 13/FMNL, FMNL2/KIAA1902/FHOD2, FMNL3/KIAA2014, DAAM1, DAAM2, DIAPH1 and DIAPH2 are Formin-homol. proteins with the FDD domain, while Fmn1, Fmn2, FHOD1 and Grid2ip/Delphilin are Formin-homol. proteins without the FDD domain. Mouse Grid2ip links glutamate receptor δ2 subunit with actin cytoskeleton and various signaling mols. Here, we identified and characterized human GRID2IP gene as well as rat Grid2ip gene by using bioinformatics. Human GRID2IP gene was identified within human genome sequence CTD-2195F21 (AC072052.6). Human GRID2IP gene, consisting of 21 exons, was mapped to human chromosome 7p22.1. Rat Grid2ip gene, consisting of 21 exons, was identified within rat genome sequence CH230-82F18 (AC126572.3). Human GRID2IP (1020 aa) showed 91.7% total-amino-acid identity with rat Grid2ip (1024 aa), and 92.7% total-amino-acid identity with mouse Grid2ip. Human GRID2IP protein was found to consist of PDZ domain (codon 94-166), GRCAH domain (codon 204-269), FH1 domain (codon 559-621), and FH2 domain (codon 640-1005). GRCAH domain identified in this study was conserved among mammalian GRID2IP orthologs and mammalian CIP98/KIAA1526 orthologs. This is the first report on comprehensive characterization of human GRID2IP gene as well as on identification of GRCAH domain.

REFERENCE COUNT: 32 THERE ARE 32 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L40 ANSWER 11 OF 11 CAPLUS COPYRIGHT 2007 ACS on STN

ACCESSION NUMBER: 2003:271243 CAPLUS
DOCUMENT NUMBER: 139:1736
TITLE: Identification and characterization of human DAAM2 gene in silico
AUTHOR(S): Katoh, Masuko; Katoh, Masaru
CORPORATE SOURCE: M&M Medical BioInformatics, Narashino, 275-0022, Japan
SOURCE: International Journal of Oncology (2003), 22(4), 915-920
CODEN: IJONES; ISSN: 1019-6439
PUBLISHER: International Journal of Oncology
DOCUMENT TYPE: Journal
LANGUAGE: English

AB WNT signals play key roles in carcinogenesis and embryogenesis through the specification of cell fate and polarity. Dishevelled proteins are implicated in the WNT - β-catenin pathway and the WNT-PCP pathway. DAAM1/KIAA0666 is a Dishevelled-binding protein transducing WNT signals to

the PCP pathway. Here, we identified and characterized DAAM2 gene by using bioinformatics. Uncharacterized FLJ34430 and KIAA0381 cDNAs were homologous to DAAM1. FLJ34430 was recombined with URB (XM_087331) in the 3'-region, and KIAA0381 was truncated in the 5'-region. Nucleotide sequence of DAAM2 cDNA was determined in silico by adding nucleotide position 1-793 of FLJ34430 onto the 5'-end of KIAA0381. DAAM2 gene consists of 27 exons, and gives rise to four splicing variants due to alternative splicing of alternative promoter type as well as of cassette exon type. DAAM2 gene was linked to the MOCS1 gene on human chromosome 6p21.3 with an interval less than 1 kb. DAAM2 mRNA was expressed in fetal heart, adult hypothalamus, eye, spinal cord, lung, prostate, kidney, and also in glioblastoma, oligodendroglioma, melanoma, mammary adenocarcinoma and chondrosarcoma. DAAM2 was a 1077-amino-acid protein with Formin-homol. FH1 and FH2 domains, which showed 68.9% total-amino-acid identity with DAAM1. Among Formin-homol. proteins, FDD (Formin-like, Diaphanous, Daam) domain was conserved in FMNL1/FMNL/KW-13, FMNL2/KIAA1902/FHOD2, DIAPH1, DIAPH2, DAAM1 and DAAM2, but not in Fmn1, Fmn2, FHOD1 and Grid2i.p. Therefore, it was concluded that FMNL1, FMNL2, DIAPH1, DIAPH2, DAAM1 and DAAM2 proteins constitute the Formin-homol. FDD subfamily.
REFERENCE COUNT: 69 THERE ARE 69 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

=> file .meeting
'EVENTLINE' IS NOT A VALID FILE NAME
Enter "HELP FILE NAMES" at an arrow prompt (=>) for a list of files that are available. If you have requested multiple files, you can specify a corrected file name or you can enter "IGNORE" to continue accessing the remaining file names entered.
ENTER A FILE NAME OR (IGNORE):ignroe
'IGNROE' IS NOT A VALID FILE NAME
Enter "HELP FILE NAMES" at an arrow prompt (=>) for a list of files that are available. If you have requested multiple files, you can specify a corrected file name or you can enter "IGNORE" to continue accessing the remaining file names entered.
ENTER A FILE NAME OR (IGNORE):ignore
'MEDICONF' IS NOT A VALID FILE NAME
Enter "HELP FILE NAMES" at an arrow prompt (=>) for a list of files that are available. If you have requested multiple files, you can specify a corrected file name or you can enter "IGNORE" to continue accessing the remaining file names entered.
ENTER A FILE NAME OR (IGNORE):ignore

COST IN U.S. DOLLARS	SINCE FILE ENTRY	TOTAL SESSION
FULL ESTIMATED COST	43.62	64.41

DISCOUNT AMOUNTS (FOR QUALIFYING ACCOUNTS)	SINCE FILE ENTRY	TOTAL SESSION
CA SUBSCRIBER PRICE	-4.68	-5.46

FILE 'AGRICOLA' ENTERED AT 10:29:19 ON 23 JAN 2007

FILE 'BIOTECHNO' ENTERED AT 10:29:19 ON 23 JAN 2007

FILE 'CONFSCI' ENTERED AT 10:29:19 ON 23 JAN 2007

FILE 'HEALSAFE' ENTERED AT 10:29:19 ON 23 JAN 2007

FILE 'IMSDRUGCONF' ENTERED AT 10:29:19 ON 23 JAN 2007

```
FILE 'LIFESCI' ENTERED AT 10:29:19 ON 23 JAN 2007
COPYRIGHT (C) 2007 Cambridge Scientific Abstracts (CSA)

FILE 'PASCAL' ENTERED AT 10:29:19 ON 23 JAN 2007
Any reproduction or dissemination in part or in full,
by means of any process and on any support whatsoever
is prohibited without the prior written agreement of INIST-CNRS.
COPYRIGHT (C) 2007 INIST-CNRS. All rights reserved.

=> KIAA1902
L41             0 FILE AGRICOLA
L42             0 FILE BIOTECHNO
L43             0 FILE CONFSCI
L44             0 FILE HEALSAFE
L45             0 FILE IMSDRUGCONF
L46             0 FILE LIFESCI
L47             2 FILE PASCAL

TOTAL FOR ALL FILES
L48             2 KIAA1902

=> dup rme
ENTER REMOVE, IDENTIFY, ONLY, OR (?):rem
ENTER L# LIST OR (END):l47
'RME' IS NOT VALID.  VALID FILE NAMES ARE 'PASCAL'
You have entered a file name of duplicates to keep that is not
referenced by any of the L#s specified for this DUPLICATE command.
The file names of duplicates that can be kept are listed above.
Please enter one of these file names.

=> dup rem
ENTER L# LIST OR (END):l47
PROCESSING COMPLETED FOR L47
L49              2 DUP REM L47 (0 DUPLICATES REMOVED)

=> d l49 ibib abs total

L49   ANSWER 1 OF 2  PASCAL  COPYRIGHT 2007 INIST-CNRS. ALL RIGHTS RESERVED. on
      STN
ACCESSION NUMBER:          2003-0265096   PASCAL
COPYRIGHT NOTICE:          Copyright .COPYRGT. 2003 INIST-CNRS. All rights
                           reserved.
TITLE (IN ENGLISH):        Identification and characterization of human FMNL1,
                           FMNL2 and FMNL3 genes in silico
AUTHOR:                    KATOH Masuko; KATOH Masaru
CORPORATE SOURCE:          M&M Medical BioInformatics, Narashino 275-0022, Japan;
                           Genetics and Cell Biology Section, Genetics Division,
                           National Cancer Center Research Institute, Tokyo
                           104-0045, Japan
SOURCE:                    International journal of oncology, (2003), 22(5),
                           1161-1168, 72 refs.
                           ISSN: 1019-6439
DOCUMENT TYPE:             Journal
BIBLIOGRAPHIC LEVEL:       Analytic
COUNTRY:                   Greece
LANGUAGE:                  English
AVAILABILITY:              INIST-26333, 354000109840200290
AN    2003-0265096   PASCAL
CP    Copyright .COPYRGT. 2003 INIST-CNRS. All rights reserved.
AB    FMNL (NM--005892.2) is a 5'-truncated partial cDNA encoding a
      Formin-homology protein related to DAAM1, DAAM2, DIAPHI and DIAPH2. Here,
      we identified three members of FMNL gene family in the human genome by
```

using bioinformatics. FMNL1 gene, corresponding to 5'-truncated KW-13 and FMNL cDNAs, was located within reference genomic contig NT--010748.9 (nucleotide position 100576-125849, forward orientation). FMNL2 gene, corresponding to KIAA1902 and FHOD2 cDNAs, was located within NT--005151.10 (nucleotide position 122465-436828, forward orientation). FMNL3 gene, corresponding to 5'-truncated DKFZp762B245 and KIAA2014 cDNAs, was located within NT--026397.10 (nucleotide position 209769-279037, reverse orientation). FMNLI, FMNL2 and FMNL3 genes encode A and B isoforms with the C-terminal divergence due to alternative splicing (cassette splicing of exon 26). FMNL1A (1100 aa), FMNL 1B (1114 aa), FMNL2A (1087 aa), FMNL2B (1093 aa), FMNL3A (1028 aa) and FMNL3B (1027 aa) consist of FDD, FH1 and FH2 domains. Total amino-acid identity were as follows: FMNL1A vs. FMNL2A, 59.3%; FMNL1A vs. FMNL3A, 56.1%; FMNL2A vs. FMNL3A, 68.6%. FMNL1 gene was mapped to human chromosome 17q21. FMNL2 gene was linked to FNBP3/HYPA gene on chromosome 2q23.3, while FMNL3 gene was linked to FNBP3L/HYPC gene on chromosome 12q13. FMNL1 mRNA was expressed in natural killer cells, Burkitt lymphoma, pancreatic cancer, prostate cancer, and lung large cell carcinoma, FMNL2 mRNA in several normal tissues, diffuse-type gastric cancer, breast cancer, chondrosarcoma, melanoma, and glioblastoma, and FMNL3 mRNA in gastric cancer. FMNL1, FMNL2 and FMNL3 might be implicated in polarity control, invasion, migration, or metastasis through regulation of the Rho-related signaling pathway.

L49 ANSWER 2 OF 2 PASCAL COPYRIGHT 2007 INIST-CNRS. ALL RIGHTS RESERVED. on STN

ACCESSION NUMBER: 2003-0234071 PASCAL
COPYRIGHT NOTICE: Copyright .COPYRGT. 2003 INIST-CNRS. All rights reserved.
TITLE (IN ENGLISH): Identification and characterization of human DAAM2 gene in silico
AUTHOR: KATOH Masuko; KATOH Masaru
CORPORATE SOURCE: M&M Medical BioInformatics, Narashino 275-0022, Japan; Genetics and Cell Biology Section, Genetics Division, National Cancer Center Research Institute, Tokyo 104-0045, Japan
SOURCE: International journal of oncology, (2003), 22(4), 915-920, 69 refs.
ISSN: 1019-6439
DOCUMENT TYPE: Journal
BIBLIOGRAPHIC LEVEL: Analytic
COUNTRY: Greece
LANGUAGE: English
AVAILABILITY: INIST-26333, 354000109364000280
AN 2003-0234071 PASCAL
CP Copyright .COPYRGT. 2003 INIST-CNRS. All rights reserved.
AB WNT signals play key roles in carcinogenesis and embryogenesis through the specification of cell fate and polarity. Dishevelled proteins are implicated in the WNT - β-catenin pathway and the WNT-PCP pathway. DAAM1/ KIAA0666 is a Dishevelled-binding protein transducing WNT signals to the PCP pathway. Here, we identified and characterized DAAM2 gene by using bioinformatics. Uncharacterized FLJ34430 and KIAA0381 cDNAs were homologous to DAAM1. FLJ34430 was recombined with URB (XM--087331) in the 3'-region, and KIAA0381 was truncated in the 5'-region. Nucleotide sequence of DAAM2 cDNA was determined in silico by adding nucleotide position 1-793 of FLJ34430 onto the 5'-end of KIAA0381. DAAM2 gene consists of 27 exons, and gives rise to four splicing variants due to alternative splicing of alternative promoter type as well as of cassette exon type. DAAM2 gene was linked to the MOCSI gene on human chromosome 6p21.3 with an interval less than 1 kb. DAAM2 mRNA was expressed in fetal heart, adult hypothalamus, eye, spinal cord, lung, prostate, kidney, and also in glioblastoma, oligodendroglioma, melanoma, mammary adenocarcinoma and chondrosarcoma. DAAM2 was a 1077-amino-acid protein with Formin-homology FH1 and FH2 domains, which showed 68.9% total-amino-acid

identity with DAAM1. Among Formin-homology proteins, FDD (Formin-like, Diaphanous, Daam) domain was conserved in FMNL1/ FMNL/KW-13, FMNL2/ KIAA1902/FHOD2, DIAPH1, DIAPH2, DAAM1 and DAAM2, but not in Fmn1, Fmn2, FHOD1 and Grid2ip. Therefore, it was concluded that FMNL1, FMNL2, DIAPH1, DIAPH2, DAAM1 and DAAM2 proteins constitute the Formin-homology FDD subfamily.

```
Connecting via Winsock to STN


Welcome to STN International!  Enter x:x

LOGINID:ssspta1641cxc

PASSWORD:
TERMINAL (ENTER 1, 2, 3, OR ?):2


* * * * * * * * * *   Welcome to STN International   * * * * * * * * * *

 NEWS  1           Web Page URLs for STN Seminar Schedule - N. America
 NEWS  2           "Ask CAS" for self-help around the clock
 NEWS  3  OCT 23   The Derwent World Patents Index suite of databases on STN
                   has been enhanced and reloaded
 NEWS  4  OCT 30   CHEMLIST enhanced with new search and display field
 NEWS  5  NOV 03   JAPIO enhanced with IPC 8 features and functionality
 NEWS  6  NOV 10   CA/CAplus F-Term thesaurus enhanced
 NEWS  7  NOV 10   STN Express with Discover! free maintenance release Version
                   8.01c now available
 NEWS  8  NOV 20   CAS Registry Number crossover limit increased to 300,000 in
                   additional databases
 NEWS  9  NOV 20   CA/CAplus to MARPAT accession number crossover limit increased
                   to 50,000
 NEWS 10  DEC 01   CAS REGISTRY updated with new ambiguity codes
 NEWS 11  DEC 11   CAS REGISTRY chemical nomenclature enhanced
 NEWS 12  DEC 14   WPIDS/WPINDEX/WPIX manual codes updated
 NEWS 13  DEC 14   GBFULL and FRFULL enhanced with IPC 8 features and
                   functionality
 NEWS 14  DEC 18   CA/CAplus pre-1967 chemical substance index entries enhanced
                   with preparation role
 NEWS 15  DEC 18   CA/CAplus patent kind codes updated
 NEWS 16  DEC 18   MARPAT to CA/CAplus accession number crossover limit increased
                   to 50,000
 NEWS 17  DEC 18   MEDLINE updated in preparation for 2007 reload
 NEWS 18  DEC 27   CA/CAplus enhanced with more pre-1907 records
 NEWS 19  JAN 08   CHEMLIST enhanced with New Zealand Inventory of Chemicals

 NEWS EXPRESS  NOVEMBER 10 CURRENT WINDOWS VERSION IS V8.01c, CURRENT
               MACINTOSH VERSION IS V6.0c(ENG) AND V6.0Jc(JP),
               AND CURRENT DISCOVER FILE IS DATED 25 SEPTEMBER 2006.

 NEWS HOURS    STN Operating Hours Plus Help Desk Availability
 NEWS LOGIN    Welcome Banner and News Items
 NEWS IPC8     For general information regarding STN implementation of IPC 8
 NEWS X25      X.25 communication option no longer available

Enter NEWS followed by the item number or name to see news on that
specific topic.

  All use of STN is subject to the provisions of the STN Customer
  agreement.  Please note that this agreement limits use to scientific
  research.  Use for software development or design or implementation
  of commercial gateways or other similar uses is prohibited and may
  result in loss of user privileges and other penalties.

* * * * * * * * * * * * * * * STN  Columbus  * * * * * * * * * * * * * * *

FILE 'HOME' ENTERED AT 15:39:26 ON 11 JAN 2007
```

```
=> file .meeting
'EVENTLINE' IS NOT A VALID FILE NAME
Enter "HELP FILE NAMES" at an arrow prompt (=>) for a list of files
that are available.  If you have requested multiple files, you can
specify a corrected file name or you can enter "IGNORE" to continue
accessing the remaining file names entered.
ENTER A FILE NAME OR (IGNORE):ignore
'MEDICONF' IS NOT A VALID FILE NAME
Enter "HELP FILE NAMES" at an arrow prompt (=>) for a list of files
that are available.  If you have requested multiple files, you can
specify a corrected file name or you can enter "IGNORE" to continue
accessing the remaining file names entered.
ENTER A FILE NAME OR (IGNORE):ignore
COST IN U.S. DOLLARS                                SINCE FILE      TOTAL
                                                         ENTRY    SESSION
FULL ESTIMATED COST                                       0.21       0.21

FILE 'AGRICOLA' ENTERED AT 15:39:51 ON 11 JAN 2007

FILE 'BIOTECHNO' ENTERED AT 15:39:51 ON 11 JAN 2007
COPYRIGHT (C) 2007 Elsevier Science B.V., Amsterdam. All rights reserved.

FILE 'CONFSCI' ENTERED AT 15:39:51 ON 11 JAN 2007
COPYRIGHT (C) 2007 Cambridge Scientific Abstracts (CSA)

FILE 'HEALSAFE' ENTERED AT 15:39:51 ON 11 JAN 2007
COPYRIGHT (C) 2007 Cambridge Scientific Abstracts (CSA)


FILE 'IMSDRUGCONF' ENTERED AT 15:39:51 ON 11 JAN 2007
COPYRIGHT (C) 2007 IMSWORLD Publications Ltd.

FILE 'LIFESCI' ENTERED AT 15:39:51 ON 11 JAN 2007
COPYRIGHT (C) 2007 Cambridge Scientific Abstracts (CSA)


FILE 'PASCAL' ENTERED AT 15:39:51 ON 11 JAN 2007
Any reproduction or dissemination in part or in full,
by means of any process and on any support whatsoever
is prohibited without the prior written agreement of INIST-CNRS.
COPYRIGHT (C) 2007 INIST-CNRS. All rights reserved.

=> (arthrit? or osteoarthrit? or anti-arthrit?) and (alpha-1-antichymotrypsin
precursor)
L1             0 FILE AGRICOLA
L2             0 FILE BIOTECHNO
L3             0 FILE CONFSCI
L4             0 FILE HEALSAFE
L5             0 FILE IMSDRUGCONF
L6             0 FILE LIFESCI
L7             0 FILE PASCAL

TOTAL FOR ALL FILES
L8             0 (ARTHRIT? OR OSTEOARTHRIT? OR ANTI-ARTHRIT?) AND (ALPHA-1-ANTICH
                 YMOTRYPSIN PRECURSOR)

=> (arthrit? or osteoarthrit? or anti-arthrit?) and (alpha(3A)chymotrypsin)
L9             0 FILE AGRICOLA
L10            4 FILE BIOTECHNO
L11            0 FILE CONFSCI
L12            0 FILE HEALSAFE
L13            0 FILE IMSDRUGCONF
L14            2 FILE LIFESCI
```

```
L15           4 FILE PASCAL

TOTAL FOR ALL FILES
L16          10 (ARTHRIT? OR OSTEOARTHRIT? OR ANTI-ARTHRIT?) AND (ALPHA(3A)
                CHYMOTRYPSIN)

=> dup rem
ENTER L# LIST OR (END):l16
DUPLICATE IS NOT AVAILABLE IN 'IMSDRUGCONF'.
ANSWERS FROM THESE FILES WILL BE CONSIDERED UNIQUE
PROCESSING COMPLETED FOR L16
L17           7 DUP REM L16 (3 DUPLICATES REMOVED)

=> l17 and (marker or biomarker)
L18           0 S L17
L19           0 FILE AGRICOLA
L20           4 S L17
L21           1 FILE BIOTECHNO
L22           0 S L17
L23           0 FILE CONFSCI
L24           0 S L17
L25           0 FILE HEALSAFE
L26           0 S L17
L27           0 FILE IMSDRUGCONF
L28           0 S L17
L29           0 FILE LIFESCI
L30           3 S L17
L31           0 FILE PASCAL

TOTAL FOR ALL FILES
L32           1 L17 AND (MARKER OR BIOMARKER)

=> d l32 ibib abs total

L32   ANSWER 1 OF 1  BIOTECHNO  COPYRIGHT 2007 Elsevier Science B.V. on STN
ACCESSION NUMBER:         1998:28378312   BIOTECHNO
TITLE:                    Linkage of cytokine genes to rheumatoid
                          arthritis. Evidence of genetic heterogeneity
AUTHOR:                   John S.; Myerscough A.; Marlow A.; Hajeer A.; Silman
                          A.; Ollier W.; Worthington J.
CORPORATE SOURCE:         Dr. S. John, ARC Epidemiology Research Unit,
                          University of Manchester, Stopford Building, Oxford
                          Road, Manchester M13 9PT, United Kingdom.
SOURCE:                   Annals of the Rheumatic Diseases, (1998), 57/6
                          (361-365), 31 reference(s)
                          CODEN: ARDIAO  ISSN: 0003-4967
DOCUMENT TYPE:            Journal; Article
COUNTRY:                  United Kingdom
LANGUAGE:                 English
SUMMARY LANGUAGE:         English
AN    1998:28378312   BIOTECHNO
AB    Objective - To investigate linkage of candidate disease susceptibility
      genes to rheumatoid arthritis (RA) in affected sibling pair
      families stratified for specific clinical features. Method - Two hundred
      RA affected sibling pair families were genotyped for informative
      microsatellite markers mapping within or less than 3cM from:
      INFα, INFγ, INFβ, IL1α, IL1β, IL1R, IL2, IL6,
      ILSR, ILSR, BCL2, CD40L, NOS3, NRAMP, α.sub.1 anti-trypsins and .
      alpha..sub.1, anti-chymotrypsin, using fluorescence
      based automated technology. Linkage was examined by defining allele
      sharing sibling pairs. This was assessed by maximum likelihood -
      inheritance by descent methods. Results - An increase in allele sharing
      was seen for IL5R in female sibling pairs (LOD 0.91, p = 0.03), for
      INFγ in sibling pairs with an affected male (LOD 0.96, p = 0.03)
```

and most significantly for IL2 in sibling pairs where one or both were persistently seronegative (LOD 1.05, p = 0.02). Conclusion - Weak evidence of linkage of RA to IL5R, IFNγ, and IL2 has been detected in clinical subsets of sibling pairs suggesting that RA is a genetically heterogeneous disease.

```
=> (arthrit? or osteoarthrit? or anti-arthrit?) and (alpha(3A)glycoprotein)
L33           0 FILE AGRICOLA
L34          28 FILE BIOTECHNO
L35           5 FILE CONFSCI
L36           0 FILE HEALSAFE
L37           0 FILE IMSDRUGCONF
L38          16 FILE LIFESCI
L39          31 FILE PASCAL

TOTAL FOR ALL FILES
L40          80 (ARTHRIT? OR OSTEOARTHRIT? OR ANTI-ARTHRIT?) AND (ALPHA(3A)
                GLYCOPROTEIN)

=> l28 and l16 and marker
L41           0 FILE LIFESCI

TOTAL FOR ALL FILES
L42           0 L28 AND L16 AND MARKER

=> l40 and (marker or biomarker)
L43           0 FILE AGRICOLA
L44           6 FILE BIOTECHNO
L45           0 FILE CONFSCI
L46           0 FILE HEALSAFE
L47           0 FILE IMSDRUGCONF
L48           2 FILE LIFESCI
L49           6 FILE PASCAL

TOTAL FOR ALL FILES
L50          14 L40 AND (MARKER OR BIOMARKER)

=> dup rem
ENTER L# LIST OR (END):l50
DUPLICATE IS NOT AVAILABLE IN 'IMSDRUGCONF'.
ANSWERS FROM THESE FILES WILL BE CONSIDERED UNIQUE
PROCESSING COMPLETED FOR L50
L51           9 DUP REM L50 (5 DUPLICATES REMOVED)

=> d l51 ibib abs total

L51   ANSWER 1 OF 9  BIOTECHNO  COPYRIGHT 2007 Elsevier Science B.V. on STN
      DUPLICATE
ACCESSION NUMBER:        2003:37098981   BIOTECHNO
TITLE:                   High resolution mapping of an arthritis
                         susceptibility locus on rat chromosome 4, and
                         characterization of regulated phenotypes
AUTHOR:                  Ribbhammar U.; Flornes L.; Backdahl L.; Luthman H.;
                         Fossum S.; Lorentzen J.C.
CORPORATE SOURCE:        J.C. Lorentzen, Department of Medicine, Rheumatology
                         Unit, Karolinska Institutet, S-171 76 Stockholm,
                         Sweden.
                         E-mail: johnny.lorentzen@cmm.ki.se
SOURCE:                  Human Molecular Genetics, (01 SEP 2003), 12/17
                         (2087-2096), 61 reference(s)
                         CODEN: HMGEE5  ISSN: 0964-6906
DOCUMENT TYPE:           Journal; Article
COUNTRY:                 United Kingdom
```

LANGUAGE: English
SUMMARY LANGUAGE: English
AN 2003:37098981 BIOTECHNO
AB The rat Natural Killer cell gene Complex (NKC) encodes molecules that can regulate immunity. It is located within an interval on DA rat chromosome 4 (RNO4) that is linked to immune-mediated inflammatory joint diseases, including oil-induced arthritis (OIA). We aimed to test the hypothesis that NKC regulates arthritis, by performing advanced mapping of arthritis and additional phenotypes induced by an intradermal injection of incomplete Freund's adjuvant-oil. Reciprocal transfer of RNO4 intervals established that alleles from DA confer arthritis susceptibility to inbred LEW.1AV1 and PVG.1AV1 rats, whereas LEW.1AV1 and PVG.1AV1 alleles confer resistance to inbred DA. Subcongenic strains with PVG.1AV1 alleles introduced on DA allowed mapping of disease predisposition to 0.8 cM on the cytogenetic band 4q42, within the quantitative trait locus oil-induced arthritis-2 (Oia2), but outside the NKC. Alleles in Oia2 regulated arthritis in an additive fashion, and determined arthritis incidence, severity and day of onset, in both males and females. Besides macroscopic joint-inflammation, Oia2 also regulated other oil-induced phenotypes, including lymphoplasia and plasma levels of the inflammation marker .alpha.1-acid glycoprotein. The high-impact Oia2 region harbors gene sequences similar to human C3AR1, Ribosomal protein L7, DNAJA2, C-type lectins, C1s and CD163. These candidate disease genes may be of general interest, given that rat 4q42, and the syntenic mouse 6F2 and human 12p13 regions are linked to several inflammatory diseases, including rheumatoid arthritis.

L51 ANSWER 2 OF 9 BIOTECHNO COPYRIGHT 2007 Elsevier Science B.V. on STN DUPLICATE
ACCESSION NUMBER: 2002:34121673 BIOTECHNO
TITLE: Genetic links between the acute-phase response and arthritis development in rats
AUTHOR: Olofsson P.; Nordquist N.; Vingsbo-Lundberg C.; Larsson A.; Falkenberg C.; Pettersson U.; Åkerstrom B.; Holmdahl R.
CORPORATE SOURCE: P. Olofsson, Medical Inflammation Research, I11 BMC 22184, Lund, Sweden.
E-mail: peter.olofsson@inflam.lu.se
SOURCE: Arthritis and Rheumatism, (2002), 46/1 (259-268), 48 reference(s)
CODEN: ARHEAW ISSN: 0004-3591
DOCUMENT TYPE: Journal; Article
COUNTRY: United States
LANGUAGE: English
SUMMARY LANGUAGE: English
AN 2002:34121673 BIOTECHNO
AB Objective. The acute-phase inflammatory response is closely correlated with the development of rheumatoid arthritis, but the pathophysiologic role of its specific components is largely unknown. We investigated the genetic control of the acute-phase protein response in pristane-induced arthritis (PIA), which is a chronic erosive arthritis model in rats. Methods. Plasma levels of the acute-phase proteins interleukin-6 (IL-6), .alpha..sub.1-acid glycoprotein (orosomucoid), fibrinogen, and .alpha ..sub.1-inhibitor.sub.3 were quantified in 3 strains of rats during the development and progression of disease: DA and LEW.1F, which are susceptible to arthritis, and E3, which is resistant. Genetic linkage analysis was performed on an F.sub.2 intercross between E3 and DA to determine the genetic control of the acute-phase response in arthritis. Elevated levels of .alpha..sub.1-acid glycoprotein were associated with acute inflammation, whereas levels of IL-6 were increased during the entire course of the disease. Results. Using these acute-phase markers as quantitative traits

in linkage analysis revealed a colocalization of loci controlling the acute-phase response and regions previously shown to control the development of arthritis in chromosomes 10, 12, and 14. In addition, 2 loci that were not associated with arthritis were found to regulate serum levels of the acute-phase protein Apr1 (acute-phase response 1) at the telomeric end of chromosome 12 and Apr2 on chromosome 5. Conclusion. The PIA model in rats is a useful tool for understanding some of the pathways leading to chronic erosive arthritis. The analysis of acute-phase proteins in PIA and its application as quantitative traits for studying the genetics of arthritis will promote the understanding of the genetic regulation of the acute-phase response.

L51 ANSWER 3 OF 9 BIOTECHNO COPYRIGHT 2007 Elsevier Science B.V. on STN
DUPLICATE
ACCESSION NUMBER: 2002:34114039 BIOTECHNO
TITLE: Fucosylation of .alpha.1-acid glycoprotein (orosomucoid) compared with traditional biochemical markers of inflammation in recent onset rheumatoid arthritis
AUTHOR: Ryden I.; Pahlsson P.; Lundblad A.; Skogh T.
CORPORATE SOURCE: I. Ryden, Department of Clinical Chemistry, Kalmar County Hospital, S-39185 Kalmar, Sweden. E-mail: ingvar.ryden@swipnet.se
SOURCE: Clinica Chimica Acta, (2002), 317/1-2 (221-229), 16 reference(s)
CODEN: CCATAR ISSN: 0009-8981
PUBLISHER ITEM IDENT.: S0009898101008038
DOCUMENT TYPE: Journal; Article
COUNTRY: Netherlands
LANGUAGE: English
SUMMARY LANGUAGE: English
AN 2002:34114039 BIOTECHNO
AB Background: Fucosylation of .alpha.1-acid glycoprotein (AGP, orosomucoid) has previously been found to be increased in patients with rheumatoid arthritis. Furthermore, the degree of fucosylation has been suggested to reflect disease activity. Therefore, we investigated the fucosylation of AGP in 131 patients (96 women and 35 men) with recent onset rheumatoid arthritis (RA). We compared the results with traditional biochemical markers of inflammation, i.e. plasma concentrations of AGP (P-AGP), and C-reactive protein (P-CRP). Methods: AGP fucosylation measured with a novel lectin enzyme-linked immunosorbent assay (ELISA) was compared with a disease activity score (DAS28) and its components, and with P-AGP, and P-CRP at the time of diagnosis, and at a follow-up visit 1 year later. Results: Both men and women with RA had increased AGP fucosylation compared to healthy individuals. We found a weak correlation between AGP fucosylation and DAS28 only in men. In men with initially increased AGP fucosylation, the level of fucosylation correlated with the change in DAS28 during the first year following diagnosis. Conclusion: We conclude that AGP fucosylation is not superior to traditional markers of disease activity in RA. However, AGP fucosylation may give some additional information to traditional biochemical markers on the disease progression in men.

L51 ANSWER 4 OF 9 BIOTECHNO COPYRIGHT 2007 Elsevier Science B.V. on STN
DUPLICATE
ACCESSION NUMBER: 2001:32229360 BIOTECHNO
TITLE: Rats made congenic for OIa3 on chromosome 10 become susceptible to squalene-induced arthritis
AUTHOR: Holm B.C.; Xu H.W.; Jacobsson L.; Larsson A.; Luthman H.; Lorentzen J.C.

CORPORATE SOURCE: B.C. Holm, Rheumatology Research, Center for Molecular Medicine, S-17176 Stockholm, Sweden.
E-mail: barbro.holm@cmm.ki.se
SOURCE: Human Molecular Genetics, (15 MAR 2001), 10/6 (565-572), 43 reference(s)
CODEN: HMGEE5 ISSN: 0964-6906
DOCUMENT TYPE: Journal; Article
COUNTRY: United Kingdom
LANGUAGE: English
SUMMARY LANGUAGE: English
AN 2001:32229360 BIOTECHNO
AB Several quantitative trait loci (QTLs) regulating the risk of experimental arthritis have been identified by genome-wide linkage analyses, but only the MHC has thus far been reported to transfer arthritis susceptibility in congenic animals. We have produced a congenic strain for Oia3, a genetic factor originally identified as an oil-induced arthritis (OIA) QTL in arthritis-prone DA rats. A 46 cM telomeric region of chromosome 10 encompassing Oia3 was transferred from DA rats to MHC-identical but minutely arthritis -susceptible LEW.1AV1 rats by selective breeding. Arthritis development was provoked in Oia3-congenic rats by intradermal injection of different adjuvant oils. One successful arthritis trigger was squalene, which is approved for vaccinations in humans and has been implicated in Gulf War syndrome. The endogenous cholesterol precursor squalene induced T cell infiltration into joints and macroscopic arthritis in Oia3-congenic rats and DA rats, whereas LEW.1AV1 rats were almost resistant. Arthritis onset, O14 days post-injection, coincided with arrested body-weight gain and increased plasma levels of the inflammation markers fibrinogen and . alpha.1-acid glycoprotein. Congenic rats displayed intermediate phenotypes compared with the two parental strains, and similar to rheumatoid arthritis in humans, female preponderance was observed in Oia3-congenic rats. Finally, recombinant rat strains were constructed and were used to map a susceptibility gene(s) in females to a telomeric 4-19 cM Oia3 subregion. The experimental system described allows transformation of multifactorial arthritis susceptibility into dichotomous phenotypes.

L51 ANSWER 5 OF 9 PASCAL COPYRIGHT 2007 INIST-CNRS. ALL RIGHTS RESERVED. on STN
ACCESSION NUMBER: 1997-0125427 PASCAL
COPYRIGHT NOTICE: Copyright .COPYRGT. 1997 INIST-CNRS. All rights reserved.
TITLE (IN ENGLISH): Prediction of articular destruction in rheumatoid arthritis : Disease activity markers revisited
AUTHOR: COSTE J.; SPIRA A.; CLERC D.; PAOLOGGI J.-B.
CORPORATE SOURCE: Departement de Biotastistique et d'Informatique Medicale, Hopital Cochin, Paris, France; INSERM Unite 292, and Service de Rhumatologie, Hopital Ambroise Pare, Boulogne, France
SOURCE: Journal of rheumatology, (1997), 24(1), 28-34, 60 refs.
ISSN: 0315-162X CODEN: JRHUA9
DOCUMENT TYPE: Journal
BIBLIOGRAPHIC LEVEL: Analytic
COUNTRY: Canada
LANGUAGE: English
AVAILABILITY: INIST-16024, 354000062233910070
AN 1997-0125427 PASCAL
CP Copyright .COPYRGT. 1997 INIST-CNRS. All rights reserved.
AB Objective. To assess the predictive value for joint damage progression of commonly used disease activity or process measures in rheumatoid arthritis (RA). Methods. Seventy-two patients fulfilling the

American Rheumatism Association criteria for RA were assessed twice yearly for 2 years. Primary outcome variables were progression of articular destruction, evaluated by Sharp's method, for 6, 12, 18, and 24 month periods. Results. Regression analysis, using random effects linear models, showed that only C-reactive protein, .alpha..sub.1-acid glycoprotein, iron, and erythrocyte sedimentation rate were significantly, but not independently, associated with 6 month radiographic progression. Traditional clinical measures were not predictive. No assessed marker was able to predict longer term outcome (12 or 18 month joint damage progression). Recent onset disease and older age were also associated with more severe radiographic progression. Conclusion. The lack of association between clinical measures and laboratory markers as predictors of the progression of articular destruction is further evidence of the need to reconsider processes and outcomes in RA. This study also suggests that clinical measures and laboratory markers probably do not reflect the same underlying process, arguing against gathering these measures under the same heading of "disease activity measures."

L51 ANSWER 6 OF 9 BIOTECHNO COPYRIGHT 2007 Elsevier Science B.V. on STN
ACCESSION NUMBER: 1992:22079259 BIOTECHNO
TITLE: Interleukin-6, soluble interleukin-2 receptor and microheterogeneity of the alpha-1-acid glycoprotein: New markers of acute phase reaction?
INTERLEUKIN-6 (IL-6), LOSLICHER INTERLEUKIN-2-REZEPTOR (SIL-2R) UND MIKROHETEROGENITAT DES ALPHA-1 SAUREN GLYKOPROTEINS (AGP): NEUE MARKER DER AKUT-PHASE-REAKTION?
AUTHOR: Karrer U.; Aeschlimann A.; Fassbender K.; Vogt P.; Muller W.
CORPORATE SOURCE: Rheumatologische, Universitatsklinik, Felix Platter-Spital, Burgfelderstrasse 101,CH-4102 Basel, Switzerland.
SOURCE: Schweizerische Medizinische Wochenschrift, (1992), 122/7 (233-236)
CODEN: SMWOAS ISSN: 0036-7672
DOCUMENT TYPE: Journal; Article
COUNTRY: Switzerland
LANGUAGE: German
SUMMARY LANGUAGE: German; English
AN 1992:22079259 BIOTECHNO
AB Cytokines and the different glycosylation profiles of some acute phase proteins appear to be of great value in investigating the activity of inflammatory rheumatic diseases. Using an ELISA to measure the serum concentration of sIL-2R and IL-6 and an affinity electrophoresis with Concanavalin A as a lectin to determine the microheterogenity of the alpha-1-acid-glycoprotein (AGP), we tested the sera of 63 patients with various rheumatic and infectious diseases and 17 healthy persons and compared the results with the usual markers of inflammation, e.g. erythrocyte sedimentation rate (ESR) and C-reactive protein (CRP), and with the clinical activity of the disease. ESR, CRP and sIL-2R were significantly elevated ($p < 0.001$) in seropositive rheumatoid arthritis (RA) and in acute bacterial infection. ESR and CRP showed a better correlation with the clinical activity of RA than sIL-2R. Marked elevation of IL-6 was found only in 30% of RA patients in the early stage of the acute phase reaction (APR). The AGP reactivity coefficient (AGP-RC) was significantly decreased in RA ($p < 0.01$) but increased in bacterial infections ($p < 0.001$). Our results show that there is no advantage in measuring sIL-2R in the routine diagnosis of rheumatic diseases. Raised IL-6 levels seem to indicate an early stage of APR. If ESR and CRP are elevated, the AGP-RC helps to differentiate between infection and chronic inflammatory rheumatic diseases.

L51 ANSWER 7 OF 9 BIOTECHNO COPYRIGHT 2007 Elsevier Science B.V. on STN
ACCESSION NUMBER: 1991:22061926 BIOTECHNO
TITLE: Calprotectin (the L1 protein) during surgery in patients with rheumatoid arthritis
AUTHOR: Berntzen H.B.; Endresen G.K.M.; Fagerhol M.K.; Spiechowicz J.; Mowinckel P.
CORPORATE SOURCE: Oslo Sanitetsforening, Rheumatism Hospital, Akersbakken 27,N-0172 Oslo 1, Norway.
SOURCE: Scandinavian Journal of Clinical and Laboratory Investigation, (1991), 51/7 (643-650)
CODEN: SJCLAY ISSN: 0036-5513
DOCUMENT TYPE: Journal; Article
COUNTRY: United Kingdom
LANGUAGE: English
SUMMARY LANGUAGE: English
AN 1991:22061926 BIOTECHNO
AB Calprotectin (L1) is a major leukocyte protein which is released during activation or death of neutrophil granulocytes and monocytes. Previous studies have shown that L1 may be a useful marker of disease activity in patients with adult or juvenile rheumatoid arthritis (RA). In the present study, the plasma concentrations of L1 were analysed during shoulder-joint surgery in 16 patients with adult or juvenile RA. Decreased L1 concentrations were found 48 h postoperatively. Thereafter, the L1 concentrations were increased at 72 h, with a following decrease until day 14 postoperatively. In contrast, increased serum concentrations of both C-reactive protein (CRP) and orosomucoid (i.e. .alpha ..sub.1-acid glycoprotein) were found at 48 h after surgery. Plasma samples obtained before and after surgery were analysed by gel filtration. Approximately 3/4 of the plasma L1 was found in fractions corresponding to the native molecule, while the rest was detected in higher molecular mass fractions. The distribution of L1 antigen in low and high molecular mass regions did not differ between the pre- and postoperative plasma samples. The L1 protein consists of light and heavy chains. Increased serum levels of the cystic fibrosis antigen, which is identical to L1 light chain, have been described in patients with cystic fibrosis. The existence of circulating free L1 chains was presently investigated in plasma obtained before and after surgery. After gel filtration of plasma samples, no free L1 chains were detected by use of enzyme immunoassay and dot blot.

L51 ANSWER 8 OF 9 PASCAL COPYRIGHT 2007 INIST-CNRS. ALL RIGHTS RESERVED. on STN
ACCESSION NUMBER: 1991-0005127 PASCAL
TITLE (IN ENGLISH): Inflammation and cartilage metabolism in rheumatoid arthritis : studies of the blood markers hyaluronic acid, orosomucoid, and keratan sulfate
AUTHOR: POOLE A. R.; WITTER J.; ROBERTS N.; PICCOLO F.; BRANDT R.; PAQUIN J.; BARON M.
CORPORATE SOURCE: Shriners hosp. crippled children, joint diseases lab., Montreal PQ H3G 1A6, Canada
SOURCE: Arthritis and Rheumatism, (1990), 33(6), 790-799, 34 refs.
ISSN: 0004-3591 CODEN: ARHEAW
DOCUMENT TYPE: Journal
BIBLIOGRAPHIC LEVEL: Analytic
COUNTRY: United States
LANGUAGE: English
AVAILABILITY: INIST-8711, 354000005048200050
AN 1991-0005127 PASCAL
AB Single analyses of peripheral blood of rheumatoid arthritis (RA) patients showed a significant reduction in the mean value for keratan sulfate (KS) compared with that in control subjects, but the mean value for orosomucoid (OM) was elevated compared with that in control

subjects. Some RA patients displayed highly elevated levels of hyaluronic acid (HA), while others exhibited normal levels

L51 ANSWER 9 OF 9 PASCAL COPYRIGHT 2007 INIST-CNRS. ALL RIGHTS RESERVED. on STN
ACCESSION NUMBER: 1989-0057032 PASCAL
TITLE (IN ENGLISH): Serum α.sub.1 antichymotrypsin concentration as a marker of disease activity in rheumatoid arthritis
AUTHOR: CHARD M. D.; CALVIN J.; PRICE C. P.; CAWSTON T. E.; HAZLEMAN B. L.
CORPORATE SOURCE: Addenbrooke hosp., rheumatology res. unit, Cambridge CB2 2QQ, United Kingdom
SOURCE: Annals of the rheumatic Diseases, (1988), 47(8), 665-671, 22 refs.
ISSN: 0003-4967 CODEN: ARDIAO
DOCUMENT TYPE: Journal
BIBLIOGRAPHIC LEVEL: Analytic
COUNTRY: United Kingdom
LANGUAGE: English
AVAILABILITY: CNRS-6381
AN 1989-0057032 PASCAL
ABFR La concentration serique d'α.sub.1-anti-chymotrypsine reflete l'evolution de la maladie dans la polyarthrite rhumatismale. Ses avantages possibles sont discutes

=> (arthrit? or osteoarthrit? or anti-arthrit?) and (biomarker or marker)
L52 43 FILE AGRICOLA
L53 915 FILE BIOTECHNO
L54 33 FILE CONFSCI
L55 4 FILE HEALSAFE
L56 0 FILE IMSDRUGCONF
L57 634 FILE LIFESCI
L58 1798 FILE PASCAL

TOTAL FOR ALL FILES
L59 3427 (ARTHRIT? OR OSTEOARTHRIT? OR ANTI-ARTHRIT?) AND (BIOMARKER OR MARKER)

=> l59 and lumican
L60 0 FILE AGRICOLA
L61 0 FILE BIOTECHNO
L62 0 FILE CONFSCI
L63 0 FILE HEALSAFE
L64 0 FILE IMSDRUGCONF
L65 0 FILE LIFESCI
L66 0 FILE PASCAL

TOTAL FOR ALL FILES
L67 0 L59 AND LUMICAN

=> l59 and gelsolin
L68 0 FILE AGRICOLA
L69 0 FILE BIOTECHNO
L70 0 FILE CONFSCI
L71 0 FILE HEALSAFE
L72 0 FILE IMSDRUGCONF
L73 0 FILE LIFESCI
L74 0 FILE PASCAL

TOTAL FOR ALL FILES
L75 0 L59 AND GELSOLIN

```
=> l59 and (alpha(3A)glycoprotein)
L76           0 FILE AGRICOLA
L77           6 FILE BIOTECHNO
L78           0 FILE CONFSCI
L79           0 FILE HEALSAFE
L80           0 FILE IMSDRUGCONF
L81           2 FILE LIFESCI
L82           6 FILE PASCAL

TOTAL FOR ALL FILES
L83          14 L59 AND (ALPHA(3A) GLYCOPROTEIN)

=> l59 and gelsolin
L84           0 FILE AGRICOLA
L85           0 FILE BIOTECHNO
L86           0 FILE CONFSCI
L87           0 FILE HEALSAFE
L88           0 FILE IMSDRUGCONF
L89           0 FILE LIFESCI
L90           0 FILE PASCAL

TOTAL FOR ALL FILES
L91           0 L59 AND GELSOLIN

=> file .jacob
COST IN U.S. DOLLARS                                SINCE FILE      TOTAL
                                                       ENTRY    SESSION
FULL ESTIMATED COST                                    42.26      42.47

FILE 'CAPLUS' ENTERED AT 15:52:21 ON 11 JAN 2007
USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT.
PLEASE SEE "HELP USAGETERMS" FOR DETAILS.
COPYRIGHT (C) 2007 AMERICAN CHEMICAL SOCIETY (ACS)

FILE 'BIOSIS' ENTERED AT 15:52:21 ON 11 JAN 2007
Copyright (c) 2007 The Thomson Corporation

FILE 'MEDLINE' ENTERED AT 15:52:21 ON 11 JAN 2007

FILE 'EMBASE' ENTERED AT 15:52:21 ON 11 JAN 2007
Copyright (c) 2007 Elsevier B.V. All rights reserved.

FILE 'USPATFULL' ENTERED AT 15:52:21 ON 11 JAN 2007
CA INDEXING COPYRIGHT (C) 2007 AMERICAN CHEMICAL SOCIETY (ACS)

=> (arthrit? or osteoarthrit? or anti-arthrit?) and (biomarker or marker)
L92        2599 FILE CAPLUS
L93        3476 FILE BIOSIS
L94        4579 FILE MEDLINE
L95        4017 FILE EMBASE
L96       22214 FILE USPATFULL

TOTAL FOR ALL FILES
L97       36885 (ARTHRIT? OR OSTEOARTHRIT? OR ANTI-ARTHRIT?) AND (BIOMARKER OR
                MARKER)

=> l97 and (gelsolin or lumican)
L98          23 FILE CAPLUS
L99           0 FILE BIOSIS
L100          2 FILE MEDLINE
L101          1 FILE EMBASE
L102        237 FILE USPATFULL

TOTAL FOR ALL FILES
```

```
L103       263 L97 AND (GELSOLIN OR LUMICAN)

=> dup rem
ENTER L# LIST OR (END):198
PROCESSING COMPLETED FOR L98
L104         19 DUP REM L98 (4 DUPLICATES REMOVED)

=> d l104 ibib abs total

L104 ANSWER 1 OF 19  CAPLUS  COPYRIGHT 2007 ACS on STN
ACCESSION NUMBER:         2006:1356822  CAPLUS
TITLE:                    Protein profile for osteoarthritis
INVENTOR(S):              Millett, Peter J.; Sarracino, David A.; Krastins,
                          Bryan; Gobezie, Reuben
PATENT ASSIGNEE(S):       The Brigham and Women's Hospital, Inc., USA
SOURCE:                   PCT Int. Appl., 77pp.
                          CODEN: PIXXD2
DOCUMENT TYPE:            Patent
LANGUAGE:                 English
FAMILY ACC. NUM. COUNT:   1
PATENT INFORMATION:

     PATENT NO.           KIND   DATE        APPLICATION NO.         DATE
     ---------------      ----   --------    --------------------    --------
     WO 2006138646         A2    20061228    WO 2006-US23619         20060616
         W:  AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH,
             CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD,
             GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KM, KN, KP, KR,
             KZ, LA, LC, LK, LR, LS, LT, LU, LV, LY, MA, MD, MG, MK, MN, MW,
             MX, MZ, NA, NG, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RS, RU, SC,
             SD, SE, SG, SK, SL, SM, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US,
             UZ, VC, VN, ZA, ZM, ZW
         RW: AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE,
             IS, IT, LT, LU, LV, MC, NL, PL, PT, RO, SE, SI, SK, TR, BF, BJ,
             CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG, BW, GH,
             GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY,
             KG, KZ, MD, RU, TJ, TM
PRIORITY APPLN. INFO.:                       US 2005-692040P     P  20050617
AB   The present invention relates to the identification and use of protein
     expression profiles with clin. relevance to osteoarthritis (OA).
     In particular, the invention provides the identity of marker
     proteins whose expression is correlated with OA and OA progression.
     Methods and kits are described for using these protein expression profiles
     in the study and/or diagnosis of OA, in the determination of the degree of
     advancement of OA, and in the selection and/or monitoring of treatment
     regimens.  The invention also relates to the screening of drugs that
     modulate expression of these proteins or nucleic acid mols. encoding these
     proteins, in particular for the development of disease-modifying OA
     agents.

L104 ANSWER 2 OF 19  CAPLUS  COPYRIGHT 2007 ACS on STN DUPLICATE 1
ACCESSION NUMBER:         2005:156228  CAPLUS
                            Correction of: 2005:16967
DOCUMENT NUMBER:          142:192331
                            Correction of: 142:108390
TITLE:                    Quantitative RT-PCR method for the detection in blood
                          of microarray-identified rheumatoid arthritis
                          -related gene transcripts for diagnosing and
                          monitoring disease state
INVENTOR(S):              Liew, Choong-Chin
PATENT ASSIGNEE(S):       Chondrogene Limited, Can.
SOURCE:                   U.S. Pat. Appl. Publ., 81 pp., Cont.-in-part of U.S.
                          Ser. No. 802,875.
                          CODEN: USXXCO
```

DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 31
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.		DATE
US 2005003394	A1	20050106	US 2004-812782		20040330
US 2004014059	A1	20040122	US 2002-268730		20021009
US 2006134635	A1	20060622	US 2004-802875		20040312
US 2005191637	A1	20050901	US 2004-803737		20040318
US 2005196762	A1	20050908	US 2004-803759		20040318
US 2005196763	A1	20050908	US 2004-803857		20040318
US 2005196764	A1	20050908	US 2004-803858		20040318
US 2005208505	A1	20050922	US 2004-803648		20040318
PRIORITY APPLN. INFO.:			US 1999-115125P	P	19990106
			US 2000-477148	B1	20000104
			US 2002-268730	A2	20021009
			US 2003-601518	A2	20030620
			US 2004-802875	A2	20040312
			US 2001-271955P	P	20010228
			US 2001-275017P	P	20010312
			US 2001-305340P	P	20010713
			US 2002-85783	A2	20020228

AB The present invention is directed to detection and measurement of gene transcripts and their equivalent nucleic acid products in blood for diagnosing and monitoring diseases. The present invention demonstrates that a simple drop of blood may be used to determine the quant. expression of various mRNAs that reflect the health/disease state of the subject through the use of quant. reverse transcription-polymerase chain reaction (QRT-PCR) anal. Specifically provided is anal. performed on a drop of blood for detecting, diagnosing and monitoring rheumatoid arthritis using gene-specific and/or tissue-specific primers. The present invention also describes methods by which delineation of the sequence and/or quantitation of the expression levels of disease-specific genes allows for an immediate and accurate diagnostic/prognostic test for disease or to assess the effect of a particular treatment regimen.

L104 ANSWER 3 OF 19 CAPLUS COPYRIGHT 2007 ACS on STN
ACCESSION NUMBER: 2005:316302 CAPLUS
DOCUMENT NUMBER: 142:390959
TITLE: Identification, assessment, prevention, and therapy of rheumatoid arthritis
INVENTOR(S): Guild, Braydon C.; Liao, Hua; Jones, Michael D.; Wu, Jiang; Zolg, Johannes W.
PATENT ASSIGNEE(S): Millennium Pharmaceuticals, Inc., USA
SOURCE: PCT Int. Appl., 182 pp.
CODEN: PIXXD2
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2005032328	A2	20050414	WO 2004-US15761	20040520
WO 2005032328	A3	20051215		

W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW
RW: BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM,

AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG

US 2005142569	A1	20050630	US 2004-849989	20040520
EP 1625235	A2	20060215	EP 2004-809388	20040520

R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR, BG, CZ, EE, HU, PL, SK, HR

PRIORITY APPLN. INFO.:
US 2003-472330P P 20030521
WO 2004-US15761 W 20040520

AB The authors disclose serum markers wherein changes in the levels of expression of one or more of the markers is correlated with RA.

L104 ANSWER 4 OF 19 CAPLUS COPYRIGHT 2007 ACS on STN
ACCESSION NUMBER: 2005:497356 CAPLUS
DOCUMENT NUMBER: 143:39118
TITLE: Gene expression profiling for diagnosis, prognosis, and therapy of osteoarthritis and other diseases using microarrays
INVENTOR(S): Liew, Choong-chin
PATENT ASSIGNEE(S): Chondrogene Limited, Can.
SOURCE: U.S. Pat. Appl. Publ., 157 pp., Cont.-in-part of U.S. Ser. No. 802,875.
CODEN: USXXCO
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 31
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
US 2005123938	A1	20050609	US 2004-809675	20040325
US 2004037841	A1	20040226	US 2002-85783	20020228
US 2004014059	A1	20040122	US 2002-268730	20021009
US 2006134635	A1	20060622	US 2004-802875	20040312
US 2005191637	A1	20050901	US 2004-803737	20040318
US 2005196762	A1	20050908	US 2004-803759	20040318
US 2005196763	A1	20050908	US 2004-803857	20040318
US 2005196764	A1	20050908	US 2004-803858	20040318
US 2005208505	A1	20050922	US 2004-803648	20040318
AU 2004249318	A1	20041229	AU 2004-249318	20040621
CA 2530191	A1	20041229	CA 2004-2530191	20040621
WO 2004112589	A2	20041229	WO 2004-US20836	20040621

W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW

RW: BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG

EP 1643893	A2	20060412	EP 2004-785715	20040621

R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR, BG, CZ, EE, HU, PL, SK, HR

PRIORITY APPLN. INFO.:
US 1999-115125P P 19990106
US 2000-477148 B1 20000104
US 2001-271955P P 20010228
US 2001-275017P P 20010312
US 2001-305340P P 20010713
US 2002-85783 A2 20020228

US 2002-268730	A2	20021009
US 2003-601518	A2	20030620
US 2004-802875	A2	20040312
US 2004-809675	A	20040325
WO 2004-US20836	W	20040621

AB The present invention relates to gene expression profiling for diagnosis, prognosis and therapy of osteoarthritis and other diseases using microarray methods. Specifically provided is anal. performed on a drop of blood for detecting, diagnosing and monitoring diseases using gene-specific and/or tissue-specific primers. Affymetrix Human Genome U133 and ChondroChip microarrays were used todetect differentially expressed gene transcripts in hypertension, obesity, allergy, systemic steroids, coronary artery disease, diabetes type 2, hyperlipidemia, lung disease, bladder cancer, rheumatoid arthritis, osteoarthritis, liver cancer, schizophrenia, Chagas disease, asthma, and manic depression syndrome. The present invention also describes methods by which delineation of the sequence and/or quantitation of the expression levels of disease-specific genes allows for an immediate and accurate diagnostic/prognostic test for disease or to assess the effect of a particular treatment regimen. [This abstract record is one of 3 records for this document necessitated by the large number of index entries required to fully index the document and publication system constraints.].

L104 ANSWER 5 OF 19 CAPLUS COPYRIGHT 2007 ACS on STN
ACCESSION NUMBER: 2005:325595 CAPLUS
DOCUMENT NUMBER: 142:353388
TITLE: Gene expression profiles and biomarkers for the detection of Alzheimer's disease-related and other disease-related gene transcripts in blood
INVENTOR(S): Liew, Choong-chin
PATENT ASSIGNEE(S): Chondrogene Ltd., Can.
SOURCE: U.S. Pat. Appl. Publ., 155 pp., Cont.-in-part of U.S. Ser. No. 802,875.
CODEN: USXXCO
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 31
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
US 2005079514	A1	20050414	US 2004-812827	20040330
US 2004014059	A1	20040122	US 2002-268730	20021009
US 2006134635	A1	20060622	US 2004-802875	20040312
US 2005191637	A1	20050901	US 2004-803737	20040318
US 2005196762	A1	20050908	US 2004-803759	20040318
US 2005196763	A1	20050908	US 2004-803857	20040318
US 2005196764	A1	20050908	US 2004-803858	20040318
US 2005208505	A1	20050922	US 2004-803648	20040318

PRIORITY APPLN. INFO.:

US 1999-115125P	P	19990106
US 2000-477148	B1	20000104
US 2002-268730	A2	20021009
US 2003-601518	A2	20030620
US 2004-802875	A2	20040312
US 2001-271955P	P	20010228
US 2001-275017P	P	20010312
US 2001-305340P	P	20010713
US 2002-85783	A2	20020228

AB The present invention is directed to detection and measurement of gene transcripts and their equivalent nucleic acid products in blood. Specifically provided is anal. performed on a drop of blood for detecting, diagnosing, and monitoring diseases, and in particular Alzheimer's disease, using gene-specific and/or tissue-specific primers. Affymetrix Human Genome U133 and ChondroChip microarrays were used to detect differentially

expressed gene transcripts in hypertension, obesity, allergy, systemic steroids, coronary artery disease, diabetes type 2, hyperlipidemia, lung disease, bladder cancer, rheumatoid arthritis, osteoarthritis, liver cancer, schizophrenia, Chagas disease, asthma, and manic depression syndrome. The present invention describes methods by which delineation of the sequence and/or quantitation of the expression levels of disease-specific genes allows for an immediate and accurate diagnostic/prognostic test for disease or to assess the effect of a particular treatment regimen.

L104 ANSWER 6 OF 19 CAPLUS COPYRIGHT 2007 ACS on STN
ACCESSION NUMBER: 2005:160724 CAPLUS
DOCUMENT NUMBER: 142:259424
TITLE: Gene expression profiles and biomarkers for the detection of asthma-related and other disease-related gene transcripts in blood
INVENTOR(S): Liew, Choong-Chin
PATENT ASSIGNEE(S): Chondrogene Limited, Can.
SOURCE: U.S. Pat. Appl. Publ., 156 pp., Cont.-in-part of U.S. Ser. No. 802,875.
CODEN: USXXCO
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 31
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
US 2005042630	A1	20050224	US 2004-816357	20040401
US 2004014059	A1	20040122	US 2002-268730	20021009
US 2006134635	A1	20060622	US 2004-802875	20040312
US 2005191637	A1	20050901	US 2004-803737	20040318
US 2005196762	A1	20050908	US 2004-803759	20040318
US 2005196763	A1	20050908	US 2004-803857	20040318
US 2005196764	A1	20050908	US 2004-803858	20040318
US 2005208505	A1	20050922	US 2004-803648	20040318
PRIORITY APPLN. INFO.:			US 1999-115125P P	19990106
			US 2000-477148 B1	20000104
			US 2002-268730 A2	20021009
			US 2003-601518 A2	20030620
			US 2004-802875 A2	20040312
			US 2001-271955P P	20010228
			US 2001-275017P P	20010312
			US 2001-305340P P	20010713
			US 2002-85783 A2	20020228

AB The present invention is directed to detection and measurement of gene transcripts and their equivalent nucleic acid products in blood. Specifically provided is anal. performed on a drop of blood for detecting, diagnosing, and monitoring diseases, and in particular asthma, using gene-specific and/or tissue-specific primers. Affymetrix Human Genome U133 and ChondroChip microarrays were used to detect differentially expressed gene transcripts in hypertension, obesity, allergy, systemic steroids, coronary artery disease, diabetes type 2, hyperlipidemia, lung disease, bladder cancer, rheumatoid arthritis, osteoarthritis, liver cancer, schizophrenia, Chagas disease, asthma, and manic depression syndrome. The present invention describes methods by which delineation of the sequence and/or quantitation of the expression levels of disease-specific genes allows for an immediate and accurate diagnostic/prognostic test for disease or to assess the effect of a particular treatment regimen. [This abstract record is one of three records for this document necessitated by the large number of index entries required to fully index the docoment and publication system constraints.].

L104 ANSWER 7 OF 19 CAPLUS COPYRIGHT 2007 ACS on STN DUPLICATE 2

ACCESSION NUMBER: 2005:156681 CAPLUS
Correction of: 2005:60757
DOCUMENT NUMBER: 142:216629
Correction of: 142:132329
TITLE: Gene expression profiles and biomarkers for the detection of hyperlipidemia and other disease-related gene transcripts in blood
INVENTOR(S): Liew, Choong-Chin
PATENT ASSIGNEE(S): Chondrogene Limited, Can.
SOURCE: U.S. Pat. Appl. Publ., 155 pp., Cont.-in-part of U.S. Ser. No. 802,875.
CODEN: USXXCO
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 31
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
US 2004248170	A1	20041209	US 2004-812777	20040330
US 2004014059	A1	20040122	US 2002-268730	20021009
US 2006134635	A1	20060622	US 2004-802875	20040312
US 2005191637	A1	20050901	US 2004-803737	20040318
US 2005196762	A1	20050908	US 2004-803759	20040318
US 2005196763	A1	20050908	US 2004-803857	20040318
US 2005196764	A1	20050908	US 2004-803858	20040318
US 2005208505	A1	20050922	US 2004-803648	20040318

PRIORITY APPLN. INFO.:

US 1999-115125P	P	19990106
US 2000-477148	B1	20000104
US 2002-268730	A2	20021009
US 2003-601518	A2	20030620
US 2004-802875	A2	20040312
US 2001-271955P	P	20010228
US 2001-275017P	P	20010312
US 2001-305340P	P	20010713
US 2002-85783	A2	20020228

AB The present invention is directed to detection and measurement of gene transcripts and their equivalent nucleic acid products in blood. Specifically provided is anal. performed on a drop of blood for detecting, diagnosing, and monitoring diseases, and in particular hyperlipidemia, using gene-specific and/or tissue-specific primers. Affymetrix Human Genome U133 and ChondroChip microarrays were used to detect differentially expressed gene transcripts in hypertension, obesity, allergy, systemic steroids, coronary artery disease, diabetes type 2, hyperlipidemia, lung disease, bladder cancer, rheumatoid arthritis, osteoarthritis, liver cancer, schizophrenia, Chagas disease, asthma, and manic depression syndrome. The present invention describes methods by which delineation of the sequence and/or quantitation of the expression levels of disease-specific genes allows for an immediate and accurate diagnostic/prognostic test for disease or to assess the effect of a particular treatment regimen.

L104 ANSWER 8 OF 19 CAPLUS COPYRIGHT 2007 ACS on STN DUPLICATE 3
ACCESSION NUMBER: 2005:112850 CAPLUS
DOCUMENT NUMBER: 142:153469
TITLE: Gene expression profiles and biomarkers for the detection of lung disease-related and other disease-related gene transcripts in blood
INVENTOR(S): Liew, Choong-chin
PATENT ASSIGNEE(S): Chondrogene Limited, Can.
SOURCE: U.S. Pat. Appl. Publ., 155 pp., Cont.-in-part of U.S. Ser. No. 802,875.
CODEN: USXXCO
DOCUMENT TYPE: Patent

LANGUAGE: English
FAMILY ACC. NUM. COUNT: 47
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
US 2004241728	A1	20041202	US 2004-812764	20040330
US 2004014059	A1	20040122	US 2002-268730	20021009
US 2005191637	A1	20050901	US 2004-803737	20040318
US 2005196762	A1	20050908	US 2004-803759	20040318
US 2005196763	A1	20050908	US 2004-803857	20040318
US 2005196764	A1	20050908	US 2004-803858	20040318
US 2005208505	A1	20050922	US 2004-803648	20040318
US 2004241728	A1	20041202	US 2004-812764	20040330
PRIORITY APPLN. INFO.:			US 1999-115125P	P 19990106
			US 2000-477148	B1 20000104
			US 2002-268730	A2 20021009
			US 2003-601518	A2 20030620
			US 2004-802875	A2 20040312
			US 2004-812764	A 20040330

AB The present invention is directed to detection and measurement of gene transcripts and their equivalent nucleic acid products in blood. Specifically provided is anal. performed on a drop of blood for detecting, diagnosing and monitoring diseases using gene-specific and/or tissue-specific primers. Affymetrix Human Genome U133 and ChondroChip microarrays were used to detect differentially expressed gene transcripts in hypertension, obesity, allergy, systemic steroids, coronary artery disease, diabetes type 2, hyperlipidemia, lung disease, bladder cancer, rheumatoid arthritis, osteoarthritis, liver cancer, schizophrenia, Chagas disease, asthma, and manic depression syndrome. The present invention also describes methods by which delineation of the sequence and/or quantitation of the expression levels of disease-specific genes allows for an immediate and accurate diagnostic/prognostic test for disease or to assess the effect of a particular treatment regimen. [This abstract record is one of 3 records for this document necessitated by the large number of index entries required to fully index the document and publication system constraints.].

L104 ANSWER 9 OF 19 CAPLUS COPYRIGHT 2007 ACS on STN
ACCESSION NUMBER: 2004:799449 CAPLUS
DOCUMENT NUMBER: 141:294121
TITLE: Protein markers in body fluids for diagnosing rheumatoid arthritis
INVENTOR(S): Kantor, Aaron B.; Becker, Christopher H.; Schulman, Howard
PATENT ASSIGNEE(S): Surromed Inc., USA; Ppd Biomarker Discovery Sciences, LLC
SOURCE: PCT Int. Appl., 184 pp.
CODEN: PIXXD2
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2004082617	A2	20040930	WO 2004-US7880	20040315
WO 2004082617	A3	20051208		

W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW

RW: BW, GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG

AU 2004222345	A1	20040930	AU 2004-222345	20040315
CA 2527916	A1	20040930	CA 2004-2527916	20040315
US 2005048574	A1	20050303	US 2004-801990	20040315
EP 1627076	A2	20060222	EP 2004-720815	20040315

R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR, BG, CZ, EE, HU, PL, SK

PRIORITY APPLN. INFO.:	US 2003-455037P	P	20030314
	WO 2004-US7880	W	20040315

AB Biol. markers for rheumatoid arthritis (RA) are disclosed. A high-mol.-weight fraction separated from serum samples from patients with RA or from non-RA subjects was subjected to tryptic digestion, and the peptides profiles by liquid chromatog.-electrospray ionization-mass spectrometry (LC-ESI-MS) on a high-resolution time-of-flight (TOF) instrument. Peptide markers whose expression is elevated in RA or decreased in RA are identified. Such markers may be used to diagnose and treat RA, monitor progression of the disease, evaluate therapeutic interventions, and screen candidate drugs in a clin. or preclin. trial.

L104 ANSWER 10 OF 19 CAPLUS COPYRIGHT 2007 ACS on STN

ACCESSION NUMBER:	2004:203936 CAPLUS
DOCUMENT NUMBER:	140:251758
TITLE:	Beta-2 microglobulin (B2M) and its 31 regulated gene products involved in regulation of osteoarthritis pathogenesis and chondrocyte proliferation and use thereof in screening for therapeutic B2M inhibitors
INVENTOR(S):	Marshall, Wayne E.; Liew, Choong-Chin; Zhang, Hongwei
PATENT ASSIGNEE(S):	Chondrogene Limited, Can.; Chondrogene, Inc.
SOURCE:	PCT Int. Appl., 69 pp. CODEN: PIXXD2
DOCUMENT TYPE:	Patent
LANGUAGE:	English
FAMILY ACC. NUM. COUNT:	1

PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2004020586	A2	20040311	WO 2003-US26730	20030827
WO 2004020586	A3	20050915		

W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW

RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG

US 2004127445	A1	20040701	US 2003-649959	20030826
CA 2495225	A1	20040311	CA 2003-2495225	20030827
AU 2003265757	A1	20040319	AU 2003-265757	20030827
EP 1592702	A2	20051109	EP 2003-791799	20030827

R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR, BG, CZ, EE, HU, SK

PRIORITY APPLN. INFO.:	US 2002-406494P	P	20020828
	WO 2003-US26730	W	20030827

AB The invention relates to the discovery of the role of beta-2 microglobulin

(B2M) in the pathogenesis of osteoarthritis (OA) and the ability of B2M to inhibit chondrocyte proliferation. The invention further relates to the identification of genes regulated by B2M (the "B2M-related genes"). In particular, B2M is demonstrated to inhibit chondrocyte proliferation and thus its involvement in OA pathogenesis. Also disclosed are 31 biomarker, including 20 and 11 up- and down-regulated genes (with corresponding Unigene or GenBank Accession Number provided), in response to OA treatment of chondrocytes with B2M.

L104 ANSWER 11 OF 19 CAPLUS COPYRIGHT 2007 ACS on STN
ACCESSION NUMBER: 2005:1997 CAPLUS
DOCUMENT NUMBER: 142:111841
TITLE: Gene expression profiles and biomarkers for the detection of depression-related and other disease-related gene transcripts in blood
INVENTOR(S): Liew, Choong-Chin
PATENT ASSIGNEE(S): Chondrogene Limited, Can.
SOURCE: U.S. Pat. Appl. Publ., 154 pp., Cont.-in-part of U.S. Ser. No. 802,875.
CODEN: USXXCO
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 31
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.		DATE
US 2004265868	A1	20041230	US 2004-812702		20040330
US 2004014059	A1	20040122	US 2002-268730		20021009
US 2006134635	A1	20060622	US 2004-802875		20040312
US 2005191637	A1	20050901	US 2004-803737		20040318
US 2005196762	A1	20050908	US 2004-803759		20040318
US 2005196763	A1	20050908	US 2004-803857		20040318
US 2005196764	A1	20050908	US 2004-803858		20040318
US 2005208505	A1	20050922	US 2004-803648		20040318
PRIORITY APPLN. INFO.:			US 1999-115125P	P	19990106
			US 2000-477148	B1	20000104
			US 2002-268730	A2	20021009
			US 2003-601518	A2	20030620
			US 2004-802875	A2	20040312
			US 2001-271955P	P	20010228
			US 2001-275017P	P	20010312
			US 2001-305340P	P	20010713
			US 2002-85783	A2	20020228

AB The present invention is directed to detection and measurement of gene transcripts and their equivalent nucleic acid products in blood. Specifically provided is anal. performed on a drop of blood for detecting, diagnosing, and monitoring diseases, and in particular mental depression, using gene-specific and/or tissue-specific primers. Affymetrix Human Genome U133 and ChondroChip microarrays were used to detect differentially expressed gene transcripts in hypertension, obesity, allergy, systemic steroids, coronary artery disease, diabetes type 2, hyperlipidemia, lung disease, bladder cancer, rheumatoid arthritis, osteoarthritis, liver cancer, schizophrenia, Chagas disease, asthma, and manic depression syndrome. The present invention describes methods by which delineation of the sequence and/or quantitation of the expression levels of disease-specific genes allows for an immediate and accurate diagnostic/prognostic test for disease or to assess the effect of a particular treatment regimen.

L104 ANSWER 12 OF 19 CAPLUS COPYRIGHT 2007 ACS on STN
ACCESSION NUMBER: 2005:60760 CAPLUS
Correction of: 2004:1036573
DOCUMENT NUMBER: 142:153477

Correction of: 142:16776

TITLE: Gene expression profiles and biomarkers for the detection of Chagas disease and other disease-related gene transcripts in blood

INVENTOR(S): Liew, Choong-Chin

PATENT ASSIGNEE(S): Chondrogene Limited, Can.

SOURCE: U.S. Pat. Appl. Publ., 154 pp., Cont.-in-part of U.S. Ser. No. 802,875.
CODEN: USXXCO

DOCUMENT TYPE: Patent

LANGUAGE: English

FAMILY ACC. NUM. COUNT: 31

PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
US 2004241729	A1	20041202	US 2004-813097	20040330
US 2004014059	A1	20040122	US 2002-268730	20021009
US 2006134635	A1	20060622	US 2004-802875	20040312
US 2005191637	A1	20050901	US 2004-803737	20040318
US 2005196762	A1	20050908	US 2004-803759	20040318
US 2005196763	A1	20050908	US 2004-803857	20040318
US 2005196764	A1	20050908	US 2004-803858	20040318
US 2005208505	A1	20050922	US 2004-803648	20040318

PRIORITY APPLN. INFO.:

US 1999-115125P	P	19990106
US 2000-477148	B1	20000104
US 2002-268730	A2	20021009
US 2003-601518	A2	20030620
US 2004-802875	A2	20040312
US 2001-271955P	P	20010228
US 2001-275017P	P	20010312
US 2001-305340P	P	20010713
US 2002-85783	A2	20020228

AB The present invention is directed to detection and measurement of gene transcripts and their equivalent nucleic acid products in blood. Specifically provided is anal. performed on a drop of blood for detecting, diagnosing, and monitoring diseases, and in particular Chagas disease, using gene-specific and/or tissue-specific primers. Affymetrix Human Genome U133 and ChondroChip microarrays were used to detect differentially expressed gene transcripts in hypertension, obesity, allergy, systemic steroids, coronary artery disease, diabetes type 2, hyperlipidemia, lung disease, bladder cancer, rheumatoid arthritis, osteoarthritis, liver cancer, schizophrenia, Chagas disease, asthma, and manic depression syndrome. The present invention describes methods by which delineation of the sequence and/or quantitation of the expression levels of disease-specific genes allows for an immediate and accurate diagnostic/prognostic test for disease or to assess the effect of a particular treatment regimen. [This abstract record is one of 3 records for this document necessitated by the large number of index entries required to fully index the document and publication system constraints.].

L104 ANSWER 13 OF 19 CAPLUS COPYRIGHT 2007 ACS on STN

ACCESSION NUMBER: 2005:60755 CAPLUS
Correction of: 2004:1036570

DOCUMENT NUMBER: 142:154259
Correction of: 142:36938

TITLE: Analysis of genetic information contained in peripheral blood for diagnosis, prognosis and monitoring treatment of allergy, infection and genetic disease in human

INVENTOR(S): Liew, Choong-Chin

PATENT ASSIGNEE(S): Chondrogene Limited, Can.

SOURCE: U.S. Pat. Appl. Publ., 155 pp., Cont.-in-part of U.S. Ser. No. 802,875.

CODEN: USXXCO
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 31
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
US 2004241726	A1	20041202	US 2004-812707	20040330
US 2004014059	A1	20040122	US 2002-268730	20021009
US 2006134635	A1	20060622	US 2004-802875	20040312
US 2005191637	A1	20050901	US 2004-803737	20040318
US 2005196762	A1	20050908	US 2004-803759	20040318
US 2005196763	A1	20050908	US 2004-803857	20040318
US 2005196764	A1	20050908	US 2004-803858	20040318
US 2005208505	A1	20050922	US 2004-803648	20040318
PRIORITY APPLN. INFO.:			US 1999-115125P	P 19990106
			US 2000-477148	B1 20000104
			US 2002-268730	A2 20021009
			US 2003-601518	A2 20030620
			US 2004-802875	A2 20040312
			US 2001-271955P	P 20010228
			US 2001-275017P	P 20010312
			US 2001-305340P	P 20010713
			US 2002-85783	A2 20020228

AB The present invention is directed to detection and measurement of gene transcripts and their equivalent nucleic acid products in blood. Specifically provided is anal. performed on a drop of blood for detecting, diagnosing, and monitoring diseases, and in particular allergy, using gene-specific and/or tissue-specific primers. Affymetrix Human Genome U133 and ChondroChip microarrays were used to detect differentially expressed gene transcripts in hypertension, obesity, allergy, systemic steroids, coronary artery disease, diabetes type 2, hyperlipidemia, lung disease, bladder cancer, rheumatoid arthritis, osteoarthritis, liver cancer, schizophrenia, Chagas disease, asthma, and manic depression syndrome. The present invention describes methods by which delineation of the sequence and/or quantitation of the expression levels of disease-specific genes allows for an immediate and accurate diagnostic/prognostic test for disease or to assess the effect of a particular treatment regimen. [This abstract record is one of 3 records for this document necessitated by the large number of index entries required to fully index the document and publication system constraints.].

L104 ANSWER 14 OF 19 CAPLUS COPYRIGHT 2007 ACS on STN
ACCESSION NUMBER: 2003:1007172 CAPLUS
DOCUMENT NUMBER: 140:37049
TITLE: Identification of tissue/cell specific marker genes using gene expression profiles, cartilage-specific marker genes, and diagnostic uses
INVENTOR(S): Brunner, Andreas; Hagg, Rupert; Tommasini, Roberto
PATENT ASSIGNEE(S): Millennium Biologix A.-G., Switz.
SOURCE: PCT Int. Appl., 74 pp.
CODEN: PIXXD2
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2003106706	A2	20031224	WO 2003-CH379	20030612
WO 2003106706	A3	20040318		

W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN,

CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH,
GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR,
LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NI, NO, NZ, OM,
PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, TJ, TM, TN, TR, TT,
TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW
RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY,
KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES,
FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PT, RO, SE, SI, SK, TR,
BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG

CA 2492504	A1	20031224	CA 2003-2492504		20030612
AU 2003233743	A1	20031231	AU 2003-233743		20030612
EP 1521844	A2	20050413	EP 2003-727114		20030612
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR, BG, CZ, EE, HU, SK					
US 2006008803	A1	20060112	US 2005-517756		20050802
PRIORITY APPLN. INFO.:			US 2002-388994P	P	20020614
			WO 2003-CH379	W	20030612

AB The present invention relates to a method for the identification of tissue/cell specific marker genes, a method for the determination of a disease state or developmental status of cells/tissue as well as to gene expression profiling of cartilage tissue. A cartilage array comprises a plurality of different polynucleotide chondrocyte-specific probe spots stably associated with a solid surface of a carrier, whereby each of said spots is made of a unique polynucleotide that corresponds to one specific cartilage marker gene. Said specific cartilage marker genes preferably are at least in part selected from a group of 467 genes that could be shown to be cartilage related.

L104 ANSWER 15 OF 19 CAPLUS COPYRIGHT 2007 ACS on STN

ACCESSION NUMBER:	2003:875074 CAPLUS
DOCUMENT NUMBER:	139:380024
TITLE:	Oligonucleotide probes and primers for diagnosing and monitoring autoimmune and chronic inflammatory diseases
INVENTOR(S):	Wohlgemuth, Jay; Fry, Kirk; Woodward, Robert; Ly, Ngoc
PATENT ASSIGNEE(S):	Expression Diagnostics, Inc., USA
SOURCE:	PCT Int. Appl., 877 pp. CODEN: PIXXD2
DOCUMENT TYPE:	Patent
LANGUAGE:	English
FAMILY ACC. NUM. COUNT:	8

PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.		DATE
WO 2003090694	A2	20031106	WO 2003-US13015		20030424
WO 2003090694	A3	20041118			
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NI, NO, NZ, OM, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW					
RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG					
US 2004009479	A1	20040115	US 2002-131827		20020424
US 6905827	B2	20050614			
AU 2003231132	A1	20031110	AU 2003-231132		20030424
JP 2005523038	T	20050804	JP 2003-587333		20030424
PRIORITY APPLN. INFO.:			US 2002-131827	A2	20020424
			US 2001-296764P	P	20010608
			US 2001-6290	A2	20011022

WO 2003-US13015 W 20030424

AB Methods of diagnosing or monitoring auto immune and chronic inflammatory diseases, particularly systemic lupus erythematosus and rheumatoid arthritis, in a patient by detecting the expression level of one or more genes in a patient, are described. Oligonucleotide probes and primers for diagnosing or monitoring autoimmune and chronic inflammatory diseases, particularly systemic lupus erythematosus and rheumatoid arthritis and kits or systems containing the same are also described. In one format, the gene expression system is immobilized on an array, e.g. a chip, plate, bead, pin, membrane, microfilter, oligonucleotide, cDNA, or polynucleotide microarray.

L104 ANSWER 16 OF 19 CAPLUS COPYRIGHT 2007 ACS on STN
ACCESSION NUMBER: 2003:571232 CAPLUS
DOCUMENT NUMBER: 139:128012
TITLE: Over-expressed gene markers useful in compositions, kits, and methods for identification, assessment, prevention, and therapy of rheumatoid arthritis
INVENTOR(S): Guild, Braydon C.; Liao, Hua; Jones, Michael D.; Zolg, Johannes W.; Wu, Jiang
PATENT ASSIGNEE(S): Millennium Pharmaceuticals, Inc., USA
SOURCE: PCT Int. Appl., 172 pp.
CODEN: PIXXD2
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2003060465	A2	20030724	WO 2002-US40271	20021217
WO 2003060465	A3	20031211		
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, OM, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW				
RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG				
US 2003224386	A1	20031204	US 2002-320352	20021216
AU 2002365166	A1	20030730	AU 2002-365166	20021217
EP 1454146	A2	20040908	EP 2002-803318	20021217
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR, BG, CZ, EE, SK				

PRIORITY APPLN. INFO.: US 2001-341942P P 20011219
WO 2002-US40271 W 20021217

AB The invention relates to composition, kits, and methods for detecting, characterizing, preventing, and treating human rheumatoid arthritis (RA). A variety of newly-identified markers are provided, wherein changes in the levels of expression of one or more of the markers is correlated with RA. The markers were initially identified in the synovial fluid of human patients who have been diagnosed with either erosive or non-erosive RA. Four hundred ninety markers were identified by mass spectrometry after synovial fluid samples were subjected to digestion of hyaluronic acid followed by a series of protein depletion and fractionation steps to enrich subsets of proteins from the original synovial fluid samples. Some of the identified markers were than validated in serum of patients who have been diagnosed with either erosive or non-erosive RA.

L104 ANSWER 17 OF 19 CAPLUS COPYRIGHT 2007 ACS on STN
ACCESSION NUMBER: 2003:356579 CAPLUS
DOCUMENT NUMBER: 138:366235
TITLE: Mass spectrometric analysis of protein profiles in adipogenesis and the development of regulators of adipogenesis
INVENTOR(S): Blagoev, Blagoy Andonov; Kratchmarova, Irina Hristova; Mann, Matthias; Pandey, Akilesh; Podtelejnikov, Alexandre V.
PATENT ASSIGNEE(S): MDS Proteomics, Inc., Can.
SOURCE: PCT Int. Appl., 91 pp.
CODEN: PIXXD2
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2003038055	A2	20030508	WO 2002-US35050	20021031
WO 2003038055	A3	20031120		
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, OM, PH, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZM, ZW				
RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG				
AU 2002343601	A1	20030512	AU 2002-343601	20021031
US 2004002112	A1	20040101	US 2002-285335	20021031
PRIORITY APPLN. INFO.:			US 2001-336386P P	20011031
			WO 2002-US35050 W	20021031

AB Proteins showing regulated changes in levels during the differentiation of preadipocytes are identified and their levels monitored by mass spectrometry. The genes may be used as markers of adipogenesis. The proteins and the genes may be useful as targets for the treatment of diseases associated with hyper- or hypo-adipogenesis (no data). Changes in protein profiles were analyzed when the preadipocyte cell line 3T3-L1 was induced to differentiate in vitro. Patterns were analyzed by gel electrophoresis. Major bands showing altered patterns of expression were excised from gels and analyzed by nanospray tandem mass spectrometry. This resulted in identification of several proteins known to be regulated in adipogenesis and in known proteins not previously known to be involved in adipogenesis.

L104 ANSWER 18 OF 19 CAPLUS COPYRIGHT 2007 ACS on STN
ACCESSION NUMBER: 2002:832556 CAPLUS
DOCUMENT NUMBER: 137:350862
TITLE: Gene expression profiles in bone and cartilage formation and their use in diagnosis and treatment of disease
INVENTOR(S): Clancy, Brian; Pittman, Debra M.
PATENT ASSIGNEE(S): Wyeth, John, and Brother Ltd., USA
SOURCE: PCT Int. Appl., 197 pp.
CODEN: PIXXD2
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 2
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE

WO 2002085285	A2	20021031	WO 2002-US12149	20020418
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, OM, PH, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM				
RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG				
PRIORITY APPLN. INFO.:			US 2001-284786P	P 20010418

AB The invention provides methods and compns. for diagnostic assays for detecting bone and cartilage formation and therapeutic methods and compns. for treating disease and disorders related to bone and cartilage formation or resorption, such as osteoporosis and bone fractions. The invention also provides therapeutic methods for diseases related to bone or cartilage formation or resorption. Methods for identifying therapeutics for such diseases are also provided. Marker genes that can be used to monitor bone and cartilage formation are identified on com. DNA microarrays.

L104 ANSWER 19 OF 19 CAPLUS COPYRIGHT 2007 ACS on STN
ACCESSION NUMBER: 2002:107392 CAPLUS
DOCUMENT NUMBER: 136:166062
TITLE: Endothelial cell expression patterns
INVENTOR(S): St. Croix, Brad; Kinzler, Kenneth W.; Vogelstein, Bert
PATENT ASSIGNEE(S): The Johns Hopkins University, USA
SOURCE: PCT Int. Appl., 331 pp.
CODEN: PIXXD2
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 2
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2002010217	A2	20020207	WO 2001-US24031	20010801
WO 2002010217	A3	20020906		
WO 2002010217	A9	20030206		
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZW				
RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG				
CA 2416732	A1	20020207	CA 2001-2416732	20010801
US 2003017157	A1	20030123	US 2001-918715	20010801
EP 1307557	A2	20030507	EP 2001-961827	20010801
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR				
JP 2004527210	T	20040909	JP 2002-515946	20010801
US 2005142138	A1	20050630	US 2004-979159	20041103
PRIORITY APPLN. INFO.:			US 2000-222599P	P 20000802
			US 2000-224360P	P 20000811
			US 2001-282850P	P 20010411
			US 2001-918715	A1 20010801
			WO 2001-US24031	W 20010801

AB To gain a better understanding of tumor angiogenesis, new techniques for isolating endothelial cells (ECs) and evaluating gene expression patterns

were developed. When transcripts from ECs derived from normal and malignant colorectal tissues were compared with transcripts from non-endothelial cells, over 170 genes predominantly expressed in the endothelium were identified. Comparison between normal- and tumor-derived endothelium revealed 79 differentially expressed genes, including 46 that were specifically elevated in tumor-associated endothelium. Expts. with representative genes from this group demonstrated that most were similarly expressed in the endothelium of primary lung, breast, brain, and pancreatic cancers as well as in metastatic lesions of the liver. These results demonstrate that neoplastic and normal endothelium in humans are distinct at the mol. level, and have significant implications for the development of anti-angiogenic therapies in the future.